

# 1 Disease severity-specific neutrophil signatures in blood 2 transcriptomes stratify COVID-19 patients

3 Anna C. Aschenbrenner<sup>1,2,\*</sup>, Maria Mouktaroudi<sup>3,\*</sup>, Benjamin Krämer<sup>4,\*</sup>, Nikolaos Antonakos<sup>3,\*</sup>, Marie  
4 Oestreich<sup>1,\*</sup>, Konstantina Gkizeli<sup>3,\*</sup>, Melanie Nuesch-Germano<sup>1,\*</sup>, Maria Saridaki<sup>3,\*</sup>, Lorenzo Bonaguro<sup>1,\*</sup>,  
5 Nico Reusch<sup>1,\*</sup>, Kevin Baßler<sup>1,\*</sup>, Sarandia Doulou<sup>3,\*</sup>, Rainer Knoll<sup>1,\*</sup>, Tal Pecht<sup>1,\*</sup>, Theodore S. Kapellos<sup>1,\*</sup>,  
6 Nikoletta Rovina<sup>5,\*</sup>, Charlotte Kröger<sup>1,\*</sup>, Miriam Herbert<sup>1,\*</sup>, Lisa Holsten<sup>1,\*</sup>, Arik Horne<sup>1,\*</sup>, Ioanna D.  
7 Gemünd<sup>1,\*</sup>, Shobhit Agrawal<sup>1,\*</sup>, Kilian Dahm<sup>1,\*</sup>, Martina van Uelft<sup>1,\*</sup>, Anna Drews<sup>6,\*</sup>, Lena Lenkeit<sup>1,\*</sup>, Niklas  
8 Bruse<sup>7,\*</sup>, Jelle Gerretsen<sup>7</sup>, Jannik Gierlich<sup>1</sup>, Matthias Becker<sup>6</sup>, Kristian Händler<sup>6</sup>, Michael Kraut<sup>6</sup>, Heidi  
9 Theis<sup>6</sup>, Simachew Mengiste<sup>1</sup>, Elena De Domenico<sup>6</sup>, Jonas Schulte-Schrepping<sup>1</sup>, Lea Seep<sup>1</sup>, Jan Raabe<sup>4</sup>,  
10 Christoph Hoffmeister<sup>4</sup>, Michael ToVinh<sup>4</sup>, Verena Keitel<sup>8</sup>, Gereon Rieke<sup>4</sup>, Valentina Talevi<sup>9</sup>, N. Ahmad  
11 Aziz<sup>9,10</sup>, Peter Pickkers<sup>7</sup>, Frank van de Veerdonk<sup>2</sup>, Mihai G. Netea<sup>2,11,#</sup>, Joachim L. Schultze<sup>1,6,#</sup>, Matthijs  
12 Kox<sup>7,#</sup>, Monique M.B. Breteler<sup>8,12,#</sup>, Jacob Nattermann<sup>4,#</sup>, Antonia Koutsoukou<sup>5,#</sup>, Evangelos J. Giamarellos-  
13 Bourboulis<sup>3,#</sup>, Thomas Ulas<sup>1,6,\*\*</sup>, German COVID-19 Omics Initiative (DeCOI)

## 14 15 Affiliations

16 <sup>1</sup> Genomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, 53115  
17 Bonn, Germany

18 <sup>2</sup> Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University  
19 Medical Center, Nijmegen 6525, The Netherlands

20 <sup>3</sup> 4<sup>th</sup> Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School,  
21 124 62 Athens, Greece

22 <sup>4</sup> Department I of Internal Medicine, University Hospital of Bonn (UKB), Venusberg-Campus-1, 53127,  
23 Bonn, Germany

24 <sup>5</sup> 1<sup>st</sup> Department of Pulmonary Medicine and Intensive Care Unit, National and Kapodistrian University of  
25 Athens, Medical School, 115 27, Greece

26 <sup>6</sup> Platform for Single Cell Genomics and Epigenomics at the German Center for Neurodegenerative  
27 Diseases and the University of Bonn, 53127 Bonn, Germany

28 <sup>7</sup> Department of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud  
29 University Medical Center, Nijmegen 6500 HB, The Netherlands

30 <sup>8</sup> Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf,  
31 Heinrich Heine University Düsseldorf, Düsseldorf, Germany

32 <sup>9</sup> Population Health Sciences, German Center for Neurodegenerative diseases (DZNE), Bonn, 53127  
33 Bonn, Germany

34 <sup>10</sup> Department of Neurology, Faculty of Medicine, University of Bonn, 53127 Bonn, Germany

35 <sup>11</sup> Immunology & Metabolism, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn  
36 53115, Germany

37 <sup>12</sup> Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of  
38 Bonn, Bonn, Germany

39 <sup>13</sup> German Center for Infection Research (DZIF), Germany

40  
41  
42 \* shared first authorship

43 # shared last authorship

44 § Corresponding author: [t.ulas@uni-bonn.de](mailto:t.ulas@uni-bonn.de)

45 **SUMMARY**

46 The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the  
47 world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with  
48 acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune  
49 system in the severe cases calls for a better characterization and understanding of the changes in the  
50 immune system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control  
51 donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-  
52 associated signatures were prominently enriched in severe patient groups, which was corroborated in whole  
53 blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a  
54 third cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a  
55 collection of over 2,800 samples derived from 11 different viral infections, inflammatory diseases and  
56 independent control samples revealed highly specific transcriptome signatures for COVID-19. Further,  
57 stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated  
58 systemic immune response of the host.

59

60

61 **KEYWORDS**

62 COVID-19; blood transcriptomics; transcriptome; co-expression analysis; stratification; molecular disease  
63 phenotypes; granulocytes; neutrophils; drug repurposing

## 64 INTRODUCTION

65 Pandemic spread of the recently emerged coronavirus, severe acute respiratory syndrome-coronavirus 2  
66 (SARS-CoV-2), has resulted in over 9.2 million confirmed infected individuals and over 470,000 deaths  
67 worldwide (WHO, [covid19.who.int](https://covid19.who.int), as of June 24<sup>th</sup>, 2020) from the resulting severe respiratory illness, called  
68 coronavirus disease 2019 (COVID-19) (1–3). Based on clinical observations, it has become clear that there  
69 is great variety in disease manifestation, ranging from asymptomatic cases, to flu-like symptoms, to severe  
70 cases needing mechanical ventilation, to those who do not survive (4–8). Increasing evidence suggests  
71 that the immune system plays a pivotal role in determining the severity of the disease course and it has  
72 been suggested that different molecular phenotypes might be responsible for the heterogenous outcome  
73 of COVID-19 (9–11). Identifying these molecular phenotypes might not only be important for a better  
74 understanding of the pathophysiology of the disease, but also to better define patient subgroups that are  
75 more likely to benefit from specific therapies (12–17). Indeed, while vaccines are still under development,  
76 finding an effective and patient-tailored therapeutic management for COVID-19 patients including targeting  
77 derailed immune mechanisms (18, 19) is key to mitigate the clinical burden as well as to prevent further  
78 disease fatalities (15, 16).

79 The analysis of peripheral blood-derived immune parameters in inflammatory and infectious diseases either  
80 by classical testing, including flow cytometry and serum protein measurements, or omics technologies,  
81 including transcriptomics, has been proven very valuable in the past (20–28). In COVID-19 patients,  
82 monitoring peripheral blood as a proxy for the ongoing changes within the circulating cells of the immune  
83 system, has revealed lymphopenia to correlate with disease severity (29). Similarly to SARS-CoV and  
84 MERS-CoV infections, hyperinflammation due to excessive release of proinflammatory cytokines is often  
85 observed in severe COVID-19 patients as increased serum IL-6 levels correlate with respiratory failure and  
86 adverse clinical outcomes (9, 30, 31).

87 While one can envision mild and/or early cases to benefit from antiviral drug treatments currently under  
88 clinical investigation, more severe cases may benefit from treatment to mitigate the excessive systemic  
89 immune reactions resulting in progressing pneumonia and even respiratory failure associated with severe  
90 COVID-19 (4–9). The detrimental role of the systemic inflammation in the late phase of the disease has  
91 become clear, as the cytokine storm has been associated with disease morbidity (6, 9, 30–33). Thus, a  
92 better understanding of the dysregulation of the host response to the infection leading to immunopathology  
93 is urgently needed to dissect and comprehend the immune parameters accompanying the heterogeneous  
94 disease severity seen upon SARS-CoV-2 infection.

95 Based on previous experience with other infectious diseases (20–26), we hypothesized that whole blood  
96 transcriptomes should allow us to 1) determine immune cellular characteristics and functions in COVID-19  
97 patients, 2) reveal heterogeneous molecular phenotypes of patients with similar clinical presentation, 3)

98 define commonalities and differences of COVID-19 in comparison to other inflammatory conditions and 4)  
99 predict potential drug repurposing that might counteract observed immune dysregulations.

100 Here, by using blood transcriptomes, we provide evidence for molecular subtypes within the immune  
101 response of COVID-19 patients beyond distinguishing mild and severe cases only. In addition, molecular  
102 changes in blood of severely affected patients are strikingly associated with changes in the granulocyte  
103 compartment. Furthermore, blood transcriptomes of molecular subtypes of COVID-19 patients seem to be  
104 unique in comparison to more than 2,600 samples derived from other infections, inflammatory conditions  
105 and controls. Finally, by reverse drug target prediction using patients' blood transcriptomes revealed known  
106 as well as additional new potential targets for further evaluation. Our data might also serve as a starting  
107 point for a large-scale assembly of molecular data collected during currently ongoing and future therapy  
108 trials for COVID-19 patients based on whole blood transcriptomes.

109

## 110 RESULTS

111 Whole blood transcriptomes reveal diversity of COVID-19 patients not explained by disease  
112 severity

113 To investigate the host immune response of COVID-19 patients in a systematic approach, whole blood  
114 transcriptomes were analyzed from 39 patients and 10 control donors recruited at the same hospital by  
115 RNA-sequencing (RNA-seq, **Fig. 1a**). Two-dimensional data representation using principal component  
116 analysis (PCA) showed separation of COVID-19 and control samples (**Fig. 1b**). Differential expression  
117 analysis identified 2,289 upregulated and 912 downregulated genes comparing COVID-19 and control  
118 samples ( $FC > |2|$ ,  $padj < 0.05$  / **Fig. 1c**). Upregulated genes showed greater fold changes than the  
119 downregulated genes (**Fig. 1d**). Of note, *CD177*, markedly expressed in neutrophils (34, 35), was the most  
120 prominently upregulated gene with the lowest p-value. Heightened expression was further found for several  
121 granulocyte- and monocyte-associated molecules, such as Eosinophil-derived neurotoxin (*RNASE2*),  
122 Haptoglobin (*HP*), Neutrophil elastase (*ELANE*), Olfactomedin 4 (*OLFM4*), Myeloperoxidase (*MPO*),  
123 Resistin (*RETN*), matrix metalloproteinases (*MMP8*, *MMP9*), and alarmins (*S100A8*, *S100A9*, *S100A12*),  
124 as well as for cell cycle progression-associated genes (*G0S2*, *CDC6*, *CDC25A*), type I interferon (IFN)-  
125 induced genes (*IFI27*, *IFITM3*, *CD169* (*SIGLEC1*)), but also genes with immunosuppressive functions  
126 (*IL10*, *SOCS3*, Arginase (*ARG1*)). Downregulated genes included many lymphocyte-associated factors,  
127 such as *NELL2*, *RORC*, *KLRB1*, *TCF1* (*TCF7*), Calcipressin-3 (*RCAN3*), *BACH2*, or *LEF1* (**Fig. 1d**, **Table**  
128 **S1**). Functional analysis of the differentially expressed genes (DEGs) by gene ontology enrichment analysis  
129 (GOEA) revealed granulocyte and complement activation-associated terms enriched in the upregulated  
130 DEGs and lymphocyte differentiation and T cell activation for the downregulated DEGs (**Fig. 1e**).

131 Interestingly, the T cell activation-associated genes accounting for the enrichment of this term for the  
132 upregulated DEGs included *IL10* and *CD274* (PD-L1) pointing at suppressive T cell functionality (**Table**  
133 **S1**).

134 In the current cohort, 51% of COVID-19 patients required intubation (**Table S2**). Given the heterogeneous  
135 nature of clinical manifestation of COVID-19, we sought to stratify the transcriptomic profiles by disease  
136 severity based on intubation status. Indeed, samples from patients with mild disease (requiring no  
137 intubation) clustered more closely to the control samples, while those of severe cases scattered away in  
138 the PCA (**Fig. 1f**). Consequently, there was a greater number of DEGs in blood samples from severe  
139 COVID-19 patients than in mild patients when compared to controls (**Fig. 1g**). Many of the DEGs found in  
140 the COVID-19 vs control comparison (**Fig. 1d**) were also found when separating the COVID-19 samples  
141 by severity (**Fig S1a,b**). Both, severe and mild COVID-19 in comparison to controls sh The SARS-CoV-2  
142 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical  
143 presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute  
144 respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in  
145 the severe cases calls for a better characterization and understanding of the changes in the immune  
146 system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors  
147 enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated  
148 signatures were prominently enriched in severe patient groups, which was corroborated in whole blood  
149 transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third  
150 cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a collection  
151 of over 2,600 samples derived from 11 different viral infections, inflammatory diseases and independent  
152 control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified  
153 transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic  
154 immune response of the host.ared neutrophil-specific *CD177* and *HP* expression among the most  
155 upregulated DEGs, as well as lymphocyte-associated genes such as *ABLIM1*, *NELL2*, *RCAN3*, *RORC*,  
156 *KLRB1*, among the downregulated genes (**Fig. S1a,b**). GOEA reflected these findings (**Fig. S1c**). Although  
157 all samples from COVID-19 patients showed functional enrichment for granulocyte/neutrophil activation-  
158 associated terms in general, direct comparison of severe and mild COVID-19 patients revealed this to be a  
159 heightened characteristic of the immunoprofiles in severe COVID-19 (**Fig. S1c**). Upregulated DEGs in the  
160 severe vs. mild sample comparison included *CD177*, Haptoglobin (*HP*), Neutrophil elastase (*ELANE*),  
161 Olfactomedin 4 (*OLFM4*), Myeloperoxidase (*MPO*), Resistin (*RETN*), matrix metalloproteinase *MMP8*, and  
162 alarmins (*S100A8*, *S100A12*). Whereas the type I IFN-response genes, such as *IFI27* or *IFITM3*, were not  
163 differentially regulated in severe vs. mild samples, expression of immunosuppression-associated factors  
164 was more pronounced in severe COVID-19 patients (*IL10*, *SOCS3*, Arginase (*ARG1*)) (**Fig. 1h, Table S1**).  
165 Moreover, blood transcriptomes from severe cases showed decreased expression of lymphocyte-  
166 associated genes, such as the T cell receptor chains (*TRAC*, *TRBC1*), CD3 zeta chain (*CD247*), *CD4*, *CD2*,

167 *IL2RB*, *TBET (TBX21)*, *IL7R*, as well as monocyte-associated genes, such as MHC class II molecules  
168 (*HLA-DPA1*, *HLA-DRB5*), fractalkine receptor (*CX3CR1*), Macrophage scavenger receptor (*MSR1*), or  
169 *CCL2* (**Fig. 1h, Table S1**). Differences in gene expression were not restricted to granulocyte and T cell  
170 functions only: assessing the changes in defined gene groups, e.g. transcription factors, epigenetic  
171 regulators, surface or secreted molecules, we observed many significant changes in genes that are not  
172 restricted to granulocytes or T cells, clearly indicating that other cell types are also transcriptionally altered  
173 in COVID-19 patients (**Fig. S1d**).

174 Distribution of the COVID-19 samples in the PCA revealed heterogeneity in the transcriptomic profiles (**Fig.**  
175 **1f**), which might be due to clinical heterogeneity (**Table S2**). In order to investigate this further, the top 25%  
176 of the most variable expressed genes were visualized in a heat map and samples sorted by unbiased  
177 hierarchical clustering based on their transcriptomic profiles, which resulted in more than three clusters  
178 suggesting higher transcriptional heterogeneity as explained by mild and severe COVID-19 cases vs control  
179 (**Fig. 1i**). Strikingly, neither disease, disease severity, nor the inclusion of outcome or immune classification  
180 (31), sufficiently explained the structure in the data. In order to get a better clinical understanding of the  
181 transcriptional data, we included further clinical parameters and grouped the COVID-19 patients  
182 accordingly (**Fig. 1i**). We therefore performed agglomerative hierarchical clustering using the clinical  
183 parameters that contributed most to the transcriptional differences observed across the first principal  
184 component of the dataset ( $r$ -adjusted square  $\geq 0.1$ , **Fig. S1e**). The COVID-19 patients were clustered into  
185 five clinical groups, which was the optimal number of clusters at which the intra-group variance was low  
186 and the 'clusters distance' remained high (**Fig. S1f,g**). However, comparison of this clinical parameter-  
187 based grouping of the COVID-19 patients did not match the transcriptional variability observed in the data  
188 either (**Fig. 1i**), arguing that additional molecular parameters must exist that better define the blood  
189 transcriptome structure and thereby more accurately dissect heterogeneity of the clinical manifestation of  
190 COVID-19.

191

## 192 Co-expression analysis discloses COVID-19 subgroups with distinct molecular signatures

193 Classical approaches to analyze the transcriptome data by using differential gene expression analysis  
194 based on sample groups defined by a selection of clinical parameters precluded dissection of the  
195 heterogeneity of the host immune response towards SARS-CoV-2 infection, which is evident in the high-  
196 parameter space of the transcriptome (**Fig. 1**). Co-expression analysis on the other hand identifies similarly  
197 regulated genes across samples, groups these genes into modules, which can then be explored for each  
198 patient sample individually or for entire patient groups. Applying such an approach using our established  
199 CoCena<sup>2</sup> pipeline [<https://github.com/Ulas-lab/CoCena2>] (**Fig. 2a**) for all 49 samples (39 COVID-19, 10  
200 control) independent of their clinical annotation disclosed 10 co-expression modules, designated by color

201 indianred to darkgrey, across a total of 6,085 genes included in the analysis (**Fig. S2a**). Hierarchical  
202 clustering of the samples based on their group fold changes (GFCs) for each module revealed a data-driven  
203 patient stratification assorting the samples into six groups (**Fig. S2b**), which were subsequently used in all  
204 following analyses: five different COVID-19 sample-containing groups, which only partially grouped by  
205 disease severity and illustrated heterogeneity of the immune response in COVID-19 patients, plus one  
206 group containing all control as well as four COVID-19 samples (**Fig. 2b+S2c**). Overlaying this information  
207 onto the original PCA reflected structured sample stratification as the newly defined groups clustered  
208 together (**Fig. S2d**). GFC analysis of the newly generated groups revealed group-specific enrichment of  
209 co-expressed gene modules (**Fig. 2c**). GOEA on each of the modules identified associated gene signatures  
210 displaying distinct functional characteristics, which distinguish the different sample groups G1-G6 (**Fig.**  
211 **2d+S3, Table S3**). For example, 'inflammatory response' was enriched in modules maroon, lightgreen,  
212 pink, and darkgrey, all characteristic for sample groups G1 and G2 to different extents, indicating these to  
213 possibly undergoing a more vigorous inflammatory immune reaction (**Fig. 2c+d**). Of note, G1 and G2  
214 harbour a great fraction of samples from patients with severe COVID-19 (**Fig. 2b**). Only a slight increase in  
215 the inflammation-associated module maroon, an increase in expression in the genes of darkorange  
216 (enriched in oxidative phosphorylation, mTORC1 signaling and cell cycle-associated genes), as well as a  
217 loss of expression in the gold module (connected to estrogen response genes and IL2 signaling) was  
218 indicative of the G4 sample group. G6, encompassing all control samples, was not associated with any  
219 modules connected to inflammatory processes, but showed higher expression of indianred, steelblue and  
220 gold, all functionally enriched basic cellular and metabolic processes. Extended analysis of the lightgreen  
221 module, containing 987 genes, revealed a prominent enrichment of granulocyte/neutrophil activation-  
222 related signatures (**Fig. 2e, Table S3**). To further explore this neutrophil activation signature association,  
223 we investigated possible co-expression patterns of long non-coding RNAs (lncRNA) that were reported as  
224 regulators of granulocyte function (36). *CYTOR* (also known as *Morrbid*) is a lncRNA that mediates survival  
225 of neutrophils, eosinophils, and classical monocytes in response to pro-survival cytokines (36), and  
226 interacts with the protein-coding RNAs for the catalytic PI3K isoform Phosphatidylinositol-4,5-bisphosphate  
227 3-kinase catalytic subunit beta (*PIK3CB*) and the filament Vimentin (*VIM*) (37). Interestingly, expression of  
228 *CYTOR* was significantly increased in severe COVID-19 patient group G1 ( $p < 0.001$ ) and correlated with  
229 both *PIK3CB* ( $r = 0.53$ ,  $p < 0.001$ ) and *VIM* ( $r = 0.55$ ,  $p < 0.001$ ) (**Fig. 2f**).

230 Next, we asked whether the enrichment for neutrophil activation-associated signatures in G1 and G2 is  
231 attributed to an increased relative number of granulocytes within the whole blood sample. Deconvolution of  
232 the expression values using linear support vector regression (38) showed increased relative percentages  
233 of neutrophils especially in G1 and G2 (**Fig. S2e**). G5, on the other hand, clearly displayed an increased  
234 percentage of monocytes. At the same time, lymphocyte enrichment was found to be reduced in the COVID-  
235 19 sample groups, most prominently in G1 and G2 (**Fig. S2e**). The linear deconvolution results were then  
236 validated by flow cytometry. Blood composition of COVID-19 donors confirmed an increased number of  
237 neutrophils and a decreased number of lymphocytes especially in G1 and G2 (**Fig. S2f**). As a result, the

238 neutrophil-lymphocyte ratio (NLR), a clinical marker proposed for disease severity as it has been associated  
239 with an increased systemic inflammation (39, 40), was markedly elevated in G1 and G2 compared to the  
240 control sample-containing G6, both in the computationally deconvoluted results (**Fig. 2g**) as well as  
241 measured by flow cytometry (**Fig. 2h**). Interestingly, in context of the observation that men more often  
242 progress to severe COVID-19 than women (41), G1 encompasses samples from solely male patients (**Fig.**  
243 **S2c**). Analysis of the top 20 differentially expressed transcription factors, epigenetic regulators, surface or  
244 secreted proteins for the six sample groups confirmed an increased inflammatory state, again most  
245 remarkably for G1 and G2, evident from the transcription factors of the STAT family, *STAT1*, *STAT3*,  
246 *STAT5B* and *STAT6*, surface marker *CSF3R* (G-CSF) or *FCGR3B* (CD16b), the secreted factors *GRN* or  
247 *IL1B*, or the epigenetic regulator *PADI4* (PAD4) (**Fig. S2h**).

248 We confirmed our findings of distinct molecular phenotypes in the blood of COVID-19 patients in a second  
249 independent cohort. Thirty patients, severely affected by SARS-CoV-2 infection, were sampled upon  
250 admission to the ICU. We stratified the obtained blood transcriptomes based on the module signatures from  
251 the co-expression analysis (**Fig. 2c**). The samples of the second cohort were filtered for the genes present  
252 in the COVID-19 co-expression network, group fold changes were calculated across all patients individually,  
253 and sample groups G1-G6 assigned according to their combinatorial module expression (**Fig. S4a**).  
254 Controls from the first cohort were included for comparison. Interestingly, in these ICU patients, we noted  
255 the transcriptome profiles from the second cohort to show greatest similarity to G1 and G2, which is in line  
256 with their severe phenotypes and our findings from the first cohort. Hierarchical clustering of the samples  
257 based on their group fold changes for each module stratified the samples of the second cohort into four  
258 groups (**Fig. S4b**). The control samples from the first cohort built one separate group, which we designated  
259 again as G6. To allow for group-specific comparison to the stratification within the first cohort (**Fig. 2c**), we  
260 calculated the mean GFCs of the four groups identified in the second cohort (**Fig. S4c**). Second cohort  
261 samples of the first group showed enrichment in modules lightgreen, pink and darkgrey and were thus  
262 assigned most similar to G1; the third group of the new samples showed enrichment in modules maroon  
263 and darkorange, most similar to G2; and the remaining samples were stratified into an intermediate group  
264 exhibiting stronger expression of genes from the darkorange as well as pink module indicating  
265 characteristics of both G1 and G2 (**Fig. S4c**).

266 Collectively, co-expression analysis (CoCena<sup>2</sup>) in whole blood transcriptomes reveals at least five  
267 molecular phenotypes of the host's immune response in COVID-19 patients with at least two different  
268 groups in clinically described severe COVID-19 patients. The two molecularly defined groups G1 and G2  
269 are transcriptionally characterized by a pronounced neutrophilic signature, at the same time distinct in other  
270 cellular characteristics. Such molecular classification might serve as a basis for identifying clinical  
271 surrogates for patient stratification. Since whole blood transcriptomics captures functional changes in the  
272 host's peripheral immune response across all cell types, we next sought a more detailed investigation of  
273 the granulocyte compartment within the framework of the newly identified subgroups.



274

275 Granulocytes from severe COVID-19 patients show a simultaneous increase in inflammatory and  
276 suppressive signatures

277 To investigate whether the activation signatures seen in whole blood of COVID-19 patients are not only due  
278 to disease-associated increase of the neutrophil population, granulocytes were sequenced and  
279 transcriptomes were analyzed from 11 longitudinally sampled patients (4 mild, 7 severe), resulting in 14  
280 mild and 45 severe COVID-19 samples (**Fig. 3a**). Evaluation of the relative cell type composition within  
281 each sample using linear deconvolution predicted the samples to mainly consist of neutrophils, with  
282 comparable fractions of 78.8% on average (**Fig S5a**). Exploratory analysis by PCA showed a separation  
283 between mild and severe COVID-19 patients' granulocyte samples, especially for the day 1-14 groups (**Fig.**  
284 **3B**). Differential expression analysis identified 1,496 upregulated and 1,440 downregulated genes  
285 comparing severe and mild samples from day 1-14 after first symptoms, while comparison at a late disease  
286 stage showed less differences on gene level (380 up-, 307 downregulated genes /  $FC > |2|$ ,  $padj < 0.05$  / **Fig.**  
287 **3c, Table S4**). Whole blood transcriptome analysis showed enrichment of neutrophil activation-associated  
288 signatures (**Fig. 2**). Excluding the bias of alterations in neutrophil population size across conditions, gene  
289 set enrichment analysis on granulocyte samples now uncovered that differentially expressed genes  
290 between severe and mild COVID-19 patients are indeed characterized by an increase in granulocyte  
291 activation-associated factors (**Fig. S5b**). *CD177* is part of the granulocyte activation gene set and was  
292 indeed markedly increased in severe (day 1-14) compared to mild (day 1-14) COVID-19 samples (**Fig. 3d**).  
293 Also, the alarmin *S100A6* exhibited heightened expression in granulocytes from severe COVID-19 patients  
294 (**Fig. 3d**).

295 Next, we used the CoCena<sup>2</sup> modules from the whole blood analysis (**Fig. 2c**) to identify modules that are  
296 actually driven by alterations in neutrophil activation instead of a mere increase in the neutrophil population.  
297 The genes from the modules were filtered by the union of the upregulated genes between severe and mild  
298 COVID-19 patients (either comparing at day 1-14 or 15-28 / **Fig. S5c**). After filtering, the number of DEG  
299 between granulocyte samples from mild and severe COVID-19 exceeded 100 genes per module in three  
300 of the modules. Among those modules, the genes identified in whole blood transcriptomes within the  
301 lightgreen module showed the highest overlap of 45%, maroon of 29% and pink of 7% with genes  
302 upregulated in granulocytes of severe COVID-19 patients. We then investigated the expression pattern of  
303 those modules for each individual patient in a longitudinal fashion (**Fig. 3e**). In concordance with the whole  
304 blood CoCena<sup>2</sup> results (**Fig. 2c**), modules lightgreen, maroon and pink showed a continuously elevated  
305 mean expression in the severe compared to the mild COVID-19 patients, indicated by horizontal lines  
306 showing the mean expression of the respective modules calculated only for the mild patients (**Fig. 3e**). This  
307 effect was observed irrespective of donor and of days after symptoms onset.

308 Recently, heterogeneity of neutrophils with distinct subsets associated with disease severity and phase  
309 was revealed by single cell RNA-seq analysis in blood of COVID-19 patients (42). Enrichment of the three  
310 signatures that related to severe COVID-19, in our granulocyte samples demonstrated that the findings  
311 obtained in the single-cell study were also discernible in bulk data and the results in accordance to the  
312 reported phenotypes: premature/immature, severe inflammatory, as well as severe suppressive subset  
313 marker genes were markedly enriched in granulocytes from severe COVID-19 patients in the present study  
314 (**Fig. S5d**). Further analysis of this observation on the gene level displayed the heightened expression of  
315 pre-/immature neutrophil-associated markers in severe COVID-19 patients' granulocytes, such as CD15  
316 (*FUT4*), metalloproteinase *MMP8*, alarmins (*S100A8/9*), NET formation-involved *PADI4*, or *NLRC4*, for  
317 which activating mutations have been reported to overtly trigger the inflammasome and thereby increase  
318 the risk to develop autoinflammatory syndrome (43, 44) (**Fig. 3f**). Marker genes attributed to the "mild  
319 mature activated" neutrophil subset (42), such as *ITGA4*, or *SLC38A1*, were indeed elevated as well in the  
320 mild COVID-19 patients' granulocytes of this study. In line with the single cell study, signs of an interferon  
321 response were observed irrespective of disease severity (*IFIT1*, *IFIT3*, *ISG15*), while only severe COVID-  
322 19 patients' granulocytes featured expression of genes with suppressive functionality, such as *ARG1* or  
323 PD-L1 (*CD274*) (**Fig. 3f**),

324 We next stratified the granulocyte samples based on the module signatures from the whole blood analysis.  
325 The granulocyte samples were filtered for the genes present in the COVID-19 co-expression network (**Fig.**  
326 **2c**) and the group fold changes were calculated across all patients individually, sample groups G1-G6 were  
327 assigned according to their combinatorial module expression (**Fig. 2c+3g**). For example, samples attributed  
328 to G1 showed high enrichment scores in modules lightgreen, darkgreen and pink, whereas those assigned  
329 as G2 additionally expressed the maroon module. Samples with the indianred/darkorange combination  
330 were designated as G4. Assessment of the combinatorial enrichment scores for the different modules did  
331 not lead to a corresponding sample group for all longitudinal samples from patient 1, hence it was assigned  
332 as G7. Re-analysis of *CD177*, *NLRC4*, *ARG1*, and PD-L1 (*CD274*) as a function of the assigned sample  
333 groups (**Fig. 3b-d**), showed increased expression in G1 and G2 in relation to the other groups (**Fig.**  
334 **3h+S5e**). Interestingly, the stratified patient groups in the whole blood data also depicted increased  
335 expression in G1 and G2 in comparison to the control-containing G6 (**Fig. 3i+S5f**).

336 Analysis of granulocyte samples from COVID-19 patients proved that, in addition to the relative increase in  
337 neutrophils in severe COVID-19 cases, there are indeed alterations in the transcriptional program of these  
338 cells themselves. We found enrichment of signatures typical of pre-/immature neutrophils and evidence of  
339 simultaneous inflammatory and suppressive features, arguing for a dysregulation in the peripheral  
340 granulocyte compartment. Importantly, transferring these findings back to the whole blood analysis showed  
341 that the granulocyte phenotypes were still observable within the whole blood transcriptomes.

342

343 Integration with signatures from other diseases reveals COVID-19-specific characteristics

344

345 Putting COVID-19 into context of other known diseases, we compiled whole blood transcriptomes from 11  
346 further diseases, including several viral and bacterial infections as well as immune-related disorders into  
347 one large dataset encompassing a total of 2,817 samples including the 39 COVID-19 samples from this  
348 study (**Fig. 4a, S6a, Table S5**). All in all, the dataset contains three other viral infection studies  
349 (Chikungunya (26), HIV (23) and Zika (45), n=466), seven bacterial infection studies (tuberculosis (20–23,  
350 46), bacterial sepsis and systemic inflammatory response syndrome (SIRS, n=1,578) (24), six  
351 inflammatory/autoimmune studies (systemic lupus erythematosus (47), Crohn's disease, rheumatoid  
352 arthritis (48), Ebola vaccination (25), neonatal-onset multisystem inflammatory disease (NOMID) and  
353 macrophage activation syndrome (NLRC4-MAS) (44), n=326) as well as control samples from eight  
354 different studies (n=408). To investigate how the COVID-19-specific co-expression modules can be linked  
355 to other diseases, the combined dataset was filtered for the genes present in the COVID-19 co-expression  
356 network (**Fig. 2c**) and the group fold changes were calculated across all samples (**Fig. 4b**). Additionally,  
357 cell type-specific signatures (38) and single cell-derived neutrophil subset signatures (42) (**Table S6**) were  
358 intersected with all CoCena<sup>2</sup> modules. This analysis revealed that the lightgreen module shows a high  
359 (61%) neutrophil enrichment followed by module pink (38%) and maroon (32%), which is in line with a high  
360 functional enrichment for neutrophil activation in lightgreen (**Fig. 2e, Table S3**). Genes within module  
361 lightgreen were most prominently upregulated in the severe COVID-19 group (G1) as well as in sepsis and  
362 in patients with tuberculosis and HIV infection, but not in individually occurring HIV and tuberculosis (**Fig.**  
363 **4b**). Enrichment of the neutrophil subset signatures revealed increased expression of genes found in pre-  
364 /immature neutrophils and those of inflammatory neutrophils associated with severe COVID-19. Many  
365 genes within module lightgreen are known to be related to induction of neutrophil extracellular traps (NET)  
366 (e.g. *PKC* (49), *PADI4* (50), *LTB4* (51)). Moreover, a link between excessive NET activation and tissue  
367 damage has been reported in sepsis (52). Module darkgrey shares a similar expression pattern across the  
368 disease spectrum with lightgreen and contains genes involved in platelet activation. The NET–platelet–  
369 thrombin axis has been reported to be involved in the promotion of intravascular coagulation in sepsis (53).  
370 The pink module shows the second highest neutrophil enrichment, which is dominated by the enrichment  
371 of pre-/immature neutrophils subtype signatures. It is strongly increased in sepsis, tuberculosis, after Ebola  
372 vaccination as well as in autoinflammatory diseases such as rheumatoid arthritis, NLRC4-MAS and NOMID,  
373 and shows slight overlap with the severe COVID-19 patients in group G1. It contains many epigenetic  
374 modifiers, such as *HDAC5*, *SETD1B*, or *KMT2D*, as well as *KLF2*, shown to regulate NF-κB-mediated  
375 immune functions, such as inflammation, erythropoiesis and lung development (54). Maroon is the third  
376 module with predicted neutrophil enrichment, which features genes from the “severe suppressive” subset  
377 alongside the “severe inflammatory” and pre-/immature subset signatures. It is associated with COVID-19

378 groups G2-4 and shares this characteristic with blood transcriptomes from the response to infection with  
379 Chikungunya and Zika virus or from HIV patients suffering from tuberculosis.

380  
381 A combination of single sample gene set variation analysis (ssGSVA), a non-parametric, unsupervised  
382 approach to estimate variation of gene set enrichment within each single sample, and Hallmark enrichment  
383 for each disease or inflammatory condition in the compiled dataset accentuated the findings on COVID-19  
384 blood transcriptomes in context of the other diseases (**Fig. 4c**). 'Interferon alpha and gamma responses'  
385 were enriched in acute viral infections with Chikungunya and Zika virus as well as in HIV with or without  
386 concomitant tuberculosis or after Ebola vaccination, and this enrichment was shared with COVID-19 G2.  
387 'Inflammatory response', 'IL6 and TNFA signaling' is an attribute of both, G1 and G2, to a lesser degree of  
388 G5, also Tuberculosis/HIV, and to some extent of sepsis. More prominently enriched in sepsis was  
389 'complement', 'coagulation', 'heme metabolism' and 'glycolysis' - shared by COVID-19 G1+G3; whereas  
390 'oxidative phosphorylation' and 'mTORC1 signalling' were seen for Chikungunya and Zika virus infections  
391 - shared to some extent with COVID-19 G3+G4.

392  
393 Although we observed overlaps of gene modules enriched in COVID-19 with several other infectious and  
394 immune-related diseases, each of our molecularly defined COVID-19 patient groups was characterized by  
395 a specific combination of these modules, clearly indicating the unique biology of this SARS-CoV-2 infection-  
396 mediated immune response, which needs to be considered when developing patient-stratified therapy  
397 regimens.

398

399 COVID-19 patient subgroup-specific signatures can be used to predict potential drug repurposing

400 Despite the immunologically-driven nature of COVID-19, most drugs that are currently investigated in  
401 clinical trials to combat or ameliorate COVID-19 are targeting the virus and its direct interaction partners  
402 (**Fig. 5a+S7a, Table S7**). Compounds as well as the number of clinical trials performed with anti-  
403 inflammatory, immunosuppressive, and immunomodulatory properties are immensely outnumbered by  
404 other approaches. Examining the listed target genes of currently investigated drugs in our stratified patient  
405 groups, we found 162 included in our co-expression network analysis, most of which being differentially  
406 expressed in the severe patient group G1 in comparison to G6 (**Fig. 2c+5b**). In addition, many of the  
407 regulated genes in our patient signatures are clearly not affected by the drugs that are currently investigated  
408 against COVID-19. The immunopathologies seen in COVID-19 patients, especially past their second week  
409 of symptoms, demand a host-directed, immune system-focused therapy.

410 To identify potentially beneficial drugs, we designed an *in silico* signature-based drug repurposing approach  
411 (**Fig. S7b**). To generate input signatures of interest, we characterized our stratified sample groups by  
412 identifying differentially expressed genes between groups G1-G5 and the control group G6 (**Fig. S7c**). Most

413 transcriptional differences were observed for G1 (up: 4,032, down: 4,729) and G2 (up: 2,336, down: 2,767),  
414 whereas group G3 (up: 1,193, down: 1,921), G5 (up: 1089, down: 1216), and especially G4 (up: 727, down:  
415 547) were less different to G6. Only a minor fraction of 137 DEGs was shared by all 5 comparisons. The  
416 most overlap of DEGs was observed between G1 and G2, the two groups comprising mostly severe COVID-  
417 19 patients. Nevertheless, G2 was still characterized by a large number of specific DEGs (**Fig. S7c**). GOEA  
418 of the upregulated DEGs of each comparison revealed enrichment of genes in the context of 'neutrophil  
419 activation' and 'coagulation' in all comparisons (**Fig. S7d**). Humoral and B cell-mediated immunity terms on  
420 the other hand were enriched the strongest in G4-specific upregulated DEGs (**Fig. S7d**). Differential  
421 expression analysis for the stratified sample groups once more emphasized that neutrophils play a central  
422 role in the host's immune response against SARS-CoV-2 infection. Neutrophils, as the most abundant  
423 circulating leukocytes, have become a therapeutic target of interest in multiple disease settings in recent  
424 years (55). Two interesting target genes discussed in this context and already addressed in clinical trials  
425 are *CXCR2* and *C5AR1*. Consistent with the increased NLR in G1 and G2, we observed significant  
426 upregulation of *CXCR2* and *C5AR1* in both groups (**Fig. S7e**).

427 Using patient cluster-specific DEGs as input (**Fig. S7c, Table S8**), we searched for compounds that evoke  
428 a reverse signature in human cells via the NIH Library of Integrated Network-Based Cellular Signatures  
429 (iLINCS) (56) and the Broad Institute's Repurposing Hub (57). The best counteracting signatures for each  
430 comparison were combined with signatures for all currently investigated drugs and downloaded for further  
431 analysis, resulting in about 63,000 signatures from 940 compounds/drugs. We performed gene set  
432 enrichment analysis for all signatures against our COVID-19 patient comparisons and calculated the  
433 difference of the up- and downregulated normalized enrichment score ( $\Delta$ NES). A positive  $\Delta$ NES indicates  
434 drug signatures that reverse our COVID-19 signatures, whereas drugs with a negative  $\Delta$ NES induce  
435 signatures similar to the ones observed in COVID-19. Signatures were then grouped by k-means clustering  
436 revealing groups of drug signatures that reverse specific patient subgroup signatures (e.g. cluster 5) or  
437 those that have the highest impact on all patient subgroups (e.g. cluster 13, **Fig 5c**). Amongst the top  
438 signatures in cluster 13 are methylprednisolone ( $\Delta$ NES<sub>G1</sub>=7.13), immunoglobulins ( $\Delta$ NES<sub>G1</sub>=6.62),  
439 methotrexate ( $\Delta$ NES<sub>G1</sub>=4.21) and pevonedistat ( $\Delta$ NES<sub>G1</sub>=4.81) which are all under investigation  
440 (clinicaltrials.gov), thereby proving that our *in silico* signature-based drug repurposing approach can indeed  
441 predict drugs that have already been deemed potentially beneficial in this disease (**Fig. S7f**). Extracting the  
442 leading edge of the most frequently targeted genes by the drugs included in cluster 13 revealed alarmins,  
443 such as *S100A8* or *S100A6*, and *SERPINB1*, critical for neutrophil survival by protecting the cell from  
444 proteases released into the cytoplasm during stress (58–60). Visualizing these genes in the co-expression  
445 network deduced from the blood transcriptomes of our COVID-19 patient cohort identified most of them as  
446 part of cluster lightgreen and maroon (**Fig. S7g**). Sample group G1-specific drug signature cluster 5 also  
447 encompasses a considerable number of drugs currently being tested in clinical trials to fight COVID-19 (**Fig.**  
448 **5a+d, Table S9**). Interestingly, a lot of drug signatures in cluster 5 were related to female hormones, such  
449 as alpha-estradiol ( $\Delta$ NES<sub>G1</sub>=2.83), estradiol-cypionate ( $\Delta$ NES<sub>G1</sub>=2.78), estriol ( $\Delta$ NES<sub>G1</sub>=2.78), or

450 chlormadinone acetate used in birth control pills ( $\Delta\text{NES}_{G1}=2.74$ ), but also for example dexamethasone  
451 ( $\Delta\text{NES}_{G1}=2.65$ ) that was recently reported to reduce mortality in severe COVID-19 cases requiring  
452 intubation, while showing no benefit for patients with milder disease courses (61). The most frequently  
453 targeted genes within the signatures of cluster 5 included protein tyrosine kinase 2 beta (*PTK2B*), playing  
454 an important role for integrin-mediated neutrophil degranulation (62, 63), lysosomal protease Cathepsin D  
455 (*CTSD*) expressed in neutrophils and monocytes, as well as the inflammatory mediator Interleukin-1 $\beta$   
456 (*IL1B*) (Fig. 5e). The majority of these target genes cluster in the G1-specific lightgreen and pink, as well  
457 as in the maroon CoCena<sup>2</sup> modules. Drugs predicted to be effective for each module are presented as a  
458 resource as supplementary information for further inspection (Table S9).

459 We used stratified blood transcriptomes from COVID-19 patients in an *in silico* signature-based approach  
460 to identify potential drugs for therapeutic repurposing. Many of our identified hits are indeed already being  
461 tested in clinical trials. Further, it became evident that, apart from common therapeutic avenues to address  
462 the immune dysregulation in COVID-19 patients, there are patient groups that may benefit from treatments  
463 targeting more precisely their immune phenotype and this phenotyping could be used for enrichment of  
464 patient groups in clinical trials.

465

## 466 DISCUSSION

467 The global spread of SARS-CoV2 resulting in hundreds of thousands of COVID-19 cases urgently demands  
468 a more thorough molecular understanding of the pathophysiology of the disease (12, 17, 64, 65). While  
469 vaccines are still under development (66–68), therapeutic management of the COVID-19 patients is key to  
470 mitigate the clinical burden as well as to prevent deaths. It has become clear that there is great variety in  
471 the occurrence of disease manifestation, and dysregulation of local and systemic immune responses have  
472 been implicated in disease heterogeneity (19, 33, 64, 69, 70). Here, by applying classical bioinformatics  
473 approaches and data-driven co-expression network analysis (CoCena<sup>2</sup>) on blood transcriptomes of COVID-  
474 19 patients, we provide evidence for the existence of distinct molecular phenotypes that are not solely  
475 explained by current clinical parameters. Particularly in severe COVID-19, we detected dramatic  
476 transcriptional changes in the blood compartment with loss of T cell activation and concurrent gain of a  
477 rather unique combination of neutrophil activation signals, which was not simply due to changes in cell  
478 numbers since isolated neutrophils showed the same transcriptional changes. CoCena<sup>2</sup> allowed us to group  
479 functionally related genes into 10 major transcriptional modules with distinct expression patterns across  
480 five, on this basis newly defined COVID-19 patient groups, of which two (G1, G2) were related to severe  
481 disease courses. While pronounced neutrophil-related alterations were observed in both subgroups of  
482 severe COVID-19 patients (G1, G2), genes associated with coagulation and platelet function were mainly  
483 elevated in patients with the most highly elevated number of neutrophils as measured by flow cytometry,

484 an information that was also deduced by linear support vector regression from transcriptome data.  
485 Assessment of non-coding RNA species from whole blood transcriptomes also allowed the identification for  
486 additional regulatory circuits. For example, we identify *CYTOR*, a lncRNA associated with granulocyte  
487 survival (36) strongly upregulated in COVID-19 patient group G1, which was accompanied by strong  
488 induction of *CYTOR* interactors such as *VIM* and *PIK3CB* (37). These findings strongly support the notion  
489 that whole blood transcriptomics might not only be suitable for better understanding the systemic immune  
490 response in COVID-19 patients, but can also be used to predict novel therapeutic targets involving distinct  
491 pathophysiological mechanisms observed in COVID-19. In a 'reverse transcriptome approach', we used  
492 the specific changes observed in the COVID-19-related transcriptional modules as the bait and searched  
493 for inverse correlation in thousands of drug-based transcriptome signatures to predict potential drug  
494 candidates. Most interestingly, we identified drug candidates that might be beneficial for all COVID-19  
495 patients, but also candidates that might only be suitable for a subgroup of patients. Lastly, by comparing  
496 the transcriptional modules identified in whole blood of COVID-19 patients, we identified unique differences  
497 to other viral and bacterial infections, for which similar data were available, suggesting that blood  
498 transcriptomes might also be used diagnostically or for outcome prediction in larger clinical cohorts,  
499 treatment or vaccine trials in the near future.

500 Classical bioinformatic assessment of blood transcriptome data comparing defined groups, in this study  
501 represented by control individuals and samples derived from either mild or severe COVID-19 patients,  
502 already revealed important biology of the systemic immune response. For example, the most significantly  
503 elevated transcript was *CD177*, a cell surface molecule on neutrophils, which was enhanced in both mild  
504 and severe cases (**Fig. 1, S1**), *CD177* has also been introduced as a hallmark for Kawasaki syndrome (71),  
505 a syndrome that has been observed in several studies being increased in children and adolescents during  
506 the SARS-CoV-2 pandemic (72–74). In acute Kawasaki syndrome, elevated expression of *CD177* was  
507 associated with resistance to treatment with intravenous immunoglobulin (IVIG), a therapy in COVID-19  
508 patients that is currently investigated in clinical trials around the world (9 trials, [clinicaltrials.gov](https://clinicaltrials.gov)). Integrating  
509 the assessment of *CD177* into these trials might help to stratify patients and better predict individual therapy  
510 outcome.

511 Hierarchical clustering of the most variable genes in the dataset already hinted towards further  
512 heterogeneity among patients beyond the current clinical differentiation into mild and severe patients  
513 (**Fig.1**). Indeed, co-expression network analysis in a data-driven fashion allowed us to define five patient  
514 subgroups (G1-5) defined by 10 distinct transcriptional modules, which was corroborated in a second  
515 independent cohort (**Fig. 2+S4**). Gene transcription observed in severe COVID-19 patients in G1 clearly  
516 differed from severe G2 COVID-19 patients particularly in modules darkgrey, pink, orchid, and maroon (**Fig.**  
517 **2c**). For example, biological mechanisms related to the darkgrey module included blood coagulation,  
518 platelet activation, aggregation and degranulation, as well as cell-cell adhesion and integrin mediated  
519 signaling. These are all mechanisms that are integral to several of the complications observed in a subset

520 of severe COVID-19 patients including increased disseminated intravascular coagulation (75), venous  
521 thromboembolism (75, 76), stroke (77), or acute cor pulmonale (78), further supporting the need for  
522 advanced molecular subtyping of COVID-19 patients, as proposed here based on blood transcriptomes.  
523 This is only one prominent example of the rich information within the new structure of molecular COVID-19  
524 phenotypes that we provide here. For further inspection of the data we refer the reader to the online tool  
525 that allows to extract module and group specific gene expression information  
526 (<https://www.fastgenomics.org/>).

527 In addition to many other infectious and non-infectious diseases (20–28), whole blood transcriptomics  
528 revealed important insights into the patient structure in COVID-19 and comparative analysis provides first  
529 evidence for the unique changes elicited by this disease within the host in comparison to other infections  
530 (**Fig. 4**). While cases in G2-4 shared changes with other viral infections such as Chikungunya or Zika,  
531 mainly including interferon signature genes (*IFI16*, *IFI35*, *IFIT1*, maroon module), partial overlap to bacterial  
532 sepsis was observed for G1-G3, albeit the major sepsis module (pink) was not prominently enriched in  
533 COVID-19 patients indicating that there are distinct differences in pathology of these two diseases. Although  
534 we could establish an integrative model using historical and publicly available blood transcriptome data, we  
535 also realized that limited standardization of the experimental procedures (sample processing, library  
536 production, sequencing) between different whole blood transcriptomics studies led to the exclusion of  
537 several additional important studies. In this context, it will be of great interest whether blood transcriptomics,  
538 as it was shown for tuberculosis (20, 21), can be utilized in large enough cohorts and clinical trials for  
539 disease risk or outcome prediction in COVID-19. We propose to collect whole blood transcriptomics data  
540 in a central registry for direct inspection by the research community and provide a prototype model for such  
541 a registry on FASTGenomics. Transcriptome data have been successfully used to predict a role for specific  
542 gene networks in the drug response to certain cancer types (79–83). Considering the strong influence of  
543 the systemic immune response on severity and outcome of COVID-19, we wanted to establish, whether  
544 the global assessment of molecular subgroups of COVID-19 patients could be utilized to predict novel drug  
545 targets for this disease addressing the dysregulated peripheral immune response of the host (**Fig. 5**). Using  
546 two major databases providing transcriptome signatures to many known drugs, CLUE (83) and iLINCS (82),  
547 we designed an *in silico* signature-based drug repurposing approach, allowing us to identify candidate drugs  
548 (84) that might reverse immune pathophysiology as observed in blood transcriptomes. Some of the  
549 candidate drugs identified are currently already in clinical trials, for example Imatinib (NCT04394416,  
550 NCT04357613, NCT04346147, NCT04356495), Ruxolitinib (NCT04348071, NCT04355793,  
551 NCT04377620) or Nintedanib (NCT04338802), for which prediction was particularly high in G1 patients.  
552 These trials might benefit from assessing molecular phenotypes of immune cells thereby determining  
553 whether patients with G1 type transcriptomes benefit most from such treatment. First study reports have  
554 recently declared strong benefit for Dexamethasone treatment in severe COVID-19 cases requiring  
555 intubation, while no effect on mortality was seen for those patients who did not require respiratory support  
556 (61). Of note, drugs predicted to potentially reverse the transcriptome signatures of the severely affected



557 G1 group may have adverse effects in milder COVID-19 cases from G4 as observed in the contrasting  
558 regulation patterns in many of the clusters (**Fig. 5c**). Interestingly and in line with the reports on sexual  
559 dimorphism in COVID-19 severity and mortality (85), G1 included only male patients and many of the drugs  
560 predicted to reverse the G1-specific signatures were related to female hormones (**Fig. 5d**). However, we  
561 also predicted drugs for all COVID-19 patients already in clinical trials such as immunoglobulins (>80 trials,  
562 [clinicaltrials.gov](https://clinicaltrials.gov)), or methylprednisolone (>20 trials), findings further supporting the value of our prediction  
563 approach. Despite these promising results, strongly suggesting that reverse transcriptomics is not only of  
564 value in cancer (79–81) but might also be used to identify drugs targeting the immune pathophysiology in  
565 COVID-19, we would also like to point out current limitations of our findings that need to be addressed in  
566 future studies. Predictions will further benefit from and focused by validation studies in independent COVID-  
567 19 patient cohorts, which is to be fostered by a central database for COVID-19 patients' blood transcriptome  
568 data. Nevertheless, we used samples from different countries, illustrating the generalizability. Furthermore,  
569 the molecularly derived and prioritized drug candidates presented here might be tested in very recently  
570 introduced pre-clinical models (86) prior to starting clinical trials. Irrespective of the current shortcomings,  
571 we favor such drug candidate identification, since it is based on interrogation of molecular data directly  
572 derived from patients' immune cells involved in the ongoing processes in the disease and therefore may  
573 increase the likelihood of a beneficial effect in patients.

574 Collectively, we provide first evidence for whole blood transcriptomics to potentially become a valuable tool  
575 for distinguishing COVID-19 from other infections in cases for which pathogen detection might be difficult,  
576 for monitoring and potentially predicting outcome of the disease, to further dissect molecular phenotypes  
577 of COVID-19, particularly of the host's immune system, also along the disease course over time, and to  
578 support drug target prediction for subgroups of patients. Clearly, in contrast to more sophisticated higher  
579 resolution methods, whole blood transcriptomes can be easily obtained in large clinical cohort studies and  
580 large clinical treatment trials yet providing an enormous information content about the molecular reactions  
581 of the host's immune system. We therefore propose a blood transcriptome registry following the model we  
582 introduce here on the FASTGenomics platform that would allow the scientific community to utilize the  
583 information for new clinical studies and to address further large-scale studies into pathophysiological  
584 mechanisms of the disease and enhance the chances of trials to demonstrate a clinical benefit in patients.

585 **Acknowledgements**

586

587 We thank Claudia Finnemann for perfect technical assistance.

588

589

590 **Deutsche COVID-19 Omics Initiative (DeCOI)**

591 Robert Bals, Alexander Bartholomäus, Anke Becker, Ezio Bonifacio, Peer Bork, Thomas Clavel, Maria  
592 Colome-Tatche, Andreas Diefenbach, Alexander Dilthey, Nicole Fischer, Konrad Förstner, Julien Gagneur,  
593 Alexander Goesmann, Torsten Hain, Michael Hummel, Stefan Janssen, René Kallies, Birte Kehr, Andreas  
594 Keller, Sarah Kim-Hellmuth, Christoph Klein, Oliver Kohlbacher, Jan Korbel, Ingo Kurth, Markus Landthaler,  
595 Yang Li, Kerstin Ludwig, Oliwia Makarewicz, Manja Marz, Alice McHardy, Christian Mertes, Markus Nöthen,  
596 Peter Nürnberg, Uwe Ohler, Stephan Ossowski, Jörg Overmann, Klaus Pfeffer, Alfred Pühler, Nikolaus  
597 Rajewsky, Markus Ralser, Olaf Rieß, Stephan Ripke, Ulisses Nunes da Rocha, Philip Rosenstiel, Antoine-  
598 Emmanuel Saliba, Leif Erik Sander, Birgit Sawitzki, Philipp Schiffer, Joachim L. Schultze, Alexander  
599 Sczyrba, Oliver Stegle, Jens Stoye, Fabian Theis, Janne Vehreschild, Jörg Vogel, Max von Kleist, Andreas  
600 Walker, Jörn Walter, Dagmar Wieczorek, John Ziebuhr

601

602 **Funding**

603 ACA was supported by an intramural grant from the Department of Genomics & Immunoregulation at the  
604 LIMES Institute. The work of JLS and MMBB was supported by the German Research Foundation (DFG)  
605 under Germany's Excellence Strategy – EXC2151 – 390873048 as well as by the Diet-Body-Brain  
606 Competence Cluster in Nutrition Research funded by the Federal Ministry of Education and Research (grant  
607 numbers 01EA1410C and 01EA1809C). JLS was further supported by the DFG under SCHU 950/8-1; GRK  
608 2168, TP11; SFB704, the EU project SYSCID under grant number 733100. MGN was supported by a  
609 Spinoza grant of the Netherlands Organisation for Scientific Research and an ERC Advanced Grant  
610 (833247). The study was funded in part by the Hellenic Institute for the Study of Sepsis. EJG-B received  
611 funding from the FrameWork 7 program HemoSpec and from the Horizon2020 Marie-Curie project  
612 European Sepsis Academy (granted to the National and Kapodistrian University of Athens). JN was  
613 supported by the DFG (SFB TR57, SPP1937), the DZIF, and the Hector-Foundation (M89).

614

615 **Author contributions:**

616 Conceptualization, ACA, FvdV, MGN, JLS, MK, TU; Methodology, MO, MN-G, LB, NR, KB, RK, TSK, CK,  
617 MH, LH, IG, SA, KD, LL, NB, MB, KH, MK, HT, SM, EDD, TU; Formal Analysis, ACA, MO, MN-G, LB, NR,  
618 KB, RK, TP, TSK, CK, MH, LH, AH, IG, SA, KD, LL, NB, JG, JS-S, LS, TU; Investigation, ACA, MO, MN-  
619 G, LB, NR, KB, RK, TP, TSK, CK, MH, LH, AH, IG, SA, KD, LL, NB, JS-S, JLS, TU; Resources, MM, BK,  
620 NK, KG, MS, SD, NR, JR, KMK, MTV, GR, VT, AA, PP, MK, MMBB, JN, AK, EJG-B; Writing – Original

621 Draft, ACA, MO, MN-G, LB, NR, KB, RK, TP, TSK, CK, MH, LH, AH, IG, KD, MvU, AD, JLS, TU; Writing –  
622 Review & Editing, ACA, BK, MO, MN-G, LB, NR, KB, RK, AD, FvdV, MGN, JLS, MK, MMBB, JN, EJG-B,  
623 TU; Visualization, ACA, MO, MN-G, LB, NR, KB, RK, TP, TSK, CK, MH, LH, AH, IG, SA, KD, MvU, LL, NB,  
624 JLS, TU; Supervision, ACA, JLS, MK, MMBB, JN, TU; Funding Acquisition, ACA, JLS, MMBB, EJG-B.

625

626 **Declaration of conflict of interests**

627 EJG-B has received honoraria (paid to the University of Athens) from AbbVie USA, Abbott CH, Angelini  
628 Italy, Biotest Germany, InflaRx GmbH, MSD Greece and XBiotech Inc. He has received independent  
629 educational grants from AbbVie, Abbott, Astellas Pharma, AxisShield, bioMérieux Inc, InflaRx GmbH and  
630 XBiotech Inc.

## 631 METHODS

### 632 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

#### 633 Human Cohorts

#### 634 Whole blood samples for RNA-seq analysis

635 The study was conducted between March 13 and March 30, 2020. A total of six ml of blood was sampled  
636 from patients with community-acquired pneumonia (CAP) by SARS-CoV-2 within the first 24 hours of  
637 hospital admission. CAP was defined as the presence of diffuse infiltrates in chest X-ray or chest computed  
638 tomography and positive molecular testing of respiratory secretions for SARS-CoV-2. Exclusion criteria  
639 were infection by the human immunodeficiency virus; neutropenia; and any previous intake of  
640 immunosuppressive medication (corticosteroids, anti-cytokine biologicals and biological response  
641 modifiers). The studies were conducted under the 23/12.08.2019 approval of the Ethics Committee of  
642 Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON  
643 University General Hospital. Written informed consent was provided by patients or by first-degree relatives  
644 in case of patients unable to consent. Patients were classified as severe when they were admitted to the  
645 intensive care unit because of need of mechanical ventilation; remaining patients were hospitalized in the  
646 ward and were classified as mild. The following information was recorded: white blood cell count and  
647 differential; administered treatment; and 28-day outcome. A volume of 2.5 ml of the collected blood was  
648 transferred into one PAXgene tube and stored at -80°C. The remaining was used for flow cytometry  
649 analysis. A similar amount of blood was sampled from 10 controls fully matched for age, gender and the  
650 Charlson's comorbidity index.

651 For the second cohort, whole blood samples were collected for RNA-seq analysis in PAXgene tubes from  
652 30 patients upon admission to the Intensive Care Unit of the Radboud university medical centre in  
653 Nijmegen, the Netherlands. The study was carried out in accordance with the applicable rules concerning  
654 the review of research ethics committees and informed consent. All patients or legal representatives were  
655 informed about the study details and could decline to participate. COVID-19 was diagnosed by a positive  
656 SARS-CoV-2 RT-PCR test in nasopharyngeal and throat swabs and/or by typical chest CT-scan findings.  
657 Exclusion criteria were hematological malignancies and/or active chemotherapy, solid organ transplant,  
658 auto-immune diseases, and pre-existent use of high dose corticosteroids.

659

#### 660 Granulocyte samples for RNA-seq analysis

661 This study was approved by the Institutional Review board of the University Hospital Bonn (073/19 and  
662 134/20). After providing written informed consent, 11 COVID-19 patients were included in the study. In-  
663 patients who were not able to consent at the time of study enrollment, consent was obtained after recovery.

664 COVID-19 patients who tested positive for SARS-CoV-2 RNA in nasopharyngeal swabs were recruited at  
665 the Medical Clinic I of the University Hospital Bonn between March 30 and May 17, 2020.

666 Granulocytes were isolated from EDTA-treated or heparinized peripheral blood by density centrifugation  
667 over Pancoll or Ficoll-Paque density centrifugation (density: 1.077g/ml). Granulocyte fractions were then  
668 treated with 10ml RBC lysis buffer (Biolegend) for 10min. After RBC lysis, cells were washed with DPBS  
669 and recovered by centrifugation at 300xg for 10min. Granulocyte pellets were then lysed with 500µl of  
670 QIAzol (QIAGEN), shortly vortexed and incubated 5min at RT prior storage at -80°C until RNA extraction.

671

672 Rhineland Study as control samples within the integrated dataset for disease comparison

673 Study population

674 The Rhineland Study is an ongoing community-based cohort study in which all inhabitants of two  
675 geographically defined areas in the city of Bonn, Germany aged 30–100 years are being invited to  
676 participate. Persons living in these areas are predominantly German with Caucasian ethnicity. Participation  
677 in the study is possible by invitation only. The only exclusion criterion is insufficient German language skills  
678 to give informed consent.

679 Ethical Approval

680 Approval to undertake the Rhineland Study was obtained from the ethics committee of the University of  
681 Bonn, Medical Faculty. The study is carried out in accordance with the recommendations of the International  
682 Conference on Harmonization (ICH) Good Clinical Practice (GCP) standards (ICH-GCP). Written informed  
683 consent was obtained from all participants in accordance with the Declaration of Helsinki.

684 Blood withdrawal

685 Overnight fasting blood was collected from all participants between 7:00 and 9:30 AM, including a PAXgene  
686 tube for RNA extraction.

687

## 688 **METHOD DETAILS**

### 689 **Flow cytometry techniques**

690 Whole blood cells were incubated for 15 minutes in the dark with the monoclonal antibodies anti-CD14  
691 FITC, anti-CD3 FITC, anti-CD4 FITC and anti-CD19 FITC (fluorescein isothiocyanate, emission 525nm,

692 Beckman Coulter); with anti-CD4 PE, anti-CD8 PE, and anti-CD(16+56) PE (phycoerythrin, emission  
693 575nm, Beckman Coulter); and with anti-CD45 PC5 (emission 667nm, Beckman Coulter). Fluorospheres  
694 (Beckman Coulter) were used for the determination of absolute counts. Cells were analyzed after running  
695 through the CYTOMICS FC500 flow cytometer (Beckman Coulter Co, Miami, Florida). Isotypic IgG controls  
696 stained also with anti-CD45 were used for each patient.

697

## 698 **Whole blood RNA isolation**

699 Total RNA was isolated from whole blood samples stored and stabilized in PAXgene RNA tubes using the  
700 Qiagen PAXgene Blood miRNA kit according to manufacturer's guidelines. Eluted RNA was dissolved in  
701 RNase free water. The quality and quantity of RNA was evaluated by visualization of 28S and 18S band  
702 integrity on a Tapestation 4200 system (Agilent).

703

## 704 **RNA-sequencing**

705 Total RNA was converted into double-stranded cDNA libraries using the TruSeq Stranded Total RNA with  
706 Ribo-Zero Globin kit (Illumina). In brief, ribosomal and globin mRNA were depleted from 750ng purified total  
707 RNA using biotinylated, target-specific oligos combined with Ribo-Zero rRNA removal beads, remaining  
708 RNA was fragmented using divalent cations under elevated temperature. First-strand was generated using  
709 SuperScript2 RT (Invitrogen) supplemented with Actinomycin D, followed by second-strand synthesis with  
710 dUTP replacing dTTP. 3' ends were adenylated and index adapters were ligated before subsequent PCR  
711 amplification to yield the final library. Remaining overhangs were converted into blunt ends via  
712 exonuclease/polymerase activities and enzymes were removed. Selective enrichment of DNA fragments  
713 with ligated adaptor molecules was performed using Illumina PCR primers in a 15 cycles PCR reaction,  
714 followed by purification cDNA using SPRIbeads (Beckman-Coulter). Libraries were quantified by Qubit  
715 dsDNA HS Assay (Thermo Fisher Scientific) and fragment size distribution was determined using the HS  
716 D1000 assay on a Tapestation 4200 system (Agilent). High-throughput sequencing was carried out with a  
717 NovaSeq™ 6000 Sequencing System S2 (50bp paired-end reads), and data was converted into fastq files  
718 using bcl2fastq2 v2.20.

## 719 **RNA-sequencing analysis**

720 Sequenced reads were aligned and quantified using STAR: ultrafast universal RNA-seq aligner (v2.7.3a)  
721 (87) and the human reference genome, GRCh38p13, from the Genome Reference Consortium. Raw counts  
722 were imported using DESeqDataSetFromHTSeqCount function from DESeq2 (v1.26.0) (88) and rlog  
723 transformed according to DESeq2 pipeline. DESeq2 was used for the calculation of normalized counts for  
724 each transcript using default parameters. All normalized transcripts with a maximum over all row mean

725 lower than 10 were excluded resulting in 37,526 present transcripts. Differentially expressed genes were  
726 calculated for the scenarios status (COVID-19 vs. controls), mild/severe (severe COVID-19 vs controls,  
727 mild COVID-19 vs controls, and severe vs mild COVID-19) and new\_cluster (1vs6, 2vs6, 3vs6, 4vs6, and  
728 5vs6) separately using a p-value cut-off of 0.05, an adjusted p-value (IHW) < 0.05 (independent hypothesis  
729 weighting) and a FC of 2. All present transcripts were used as input for principal component analysis. The  
730 top 25% most variable transcripts within the dataset were selected and visualized in a heat map. DEGs  
731 were visualized as DE bar plots and were used as input for volcano plots.

### 732 **Gene ontology enrichment analysis (GOEA)**

733 To test for functional enrichment within all three scenarios, we performed GOEA for up- or downregulated  
734 transcripts in the respective comparison using gene ontology set of biological processes. Gene set  
735 “c5.bp.v7.0.symbols.gmt” was obtained from the Molecular Signatures Database (MSigDB) (89).  
736 compareCluster and enrichGo functions from the R package ClusterProfiler (v3.12.0) (90) were used to  
737 determine significant enrichment (q-value<0.05) of biological processes. All present genes were used as  
738 background (universe).

### 739 **Filtering for transcription factors, epigenome, surfaceome and secretome**

740 All present transcripts were filtered and sorted by their variance in the dataset. The 20 most variable genes  
741 of each category were selected and visualized using a heat map. Transcription factor lists were extracted  
742 from (91), the epigenome gene list was literature-driven, surface and secretome markers were extracted  
743 from the Human Protein Atlas (92).

### 744 **Clustering of patients according to clinical parameters**

745 The contribution of each clinical parameter to the transcriptome in COVID-19 patients was determined using  
746 linear modelling of each parameter separately with PC1. Clinical parameters with rounded up adjusted r-  
747 square  $\geq 0.2$  were used for agglomerative hierarchical clustering of the COVID-19 patients. A dissimilarity  
748 matrix based on Gower distance was calculated using the daisy function from the cluster packages (version  
749 2.1.0). Agglomerative hierarchical clustering was performed using the hclust function, defining the method  
750 with a setting for ward.D2 method linkage. We evaluated the clustering by extracting clusters statistics using  
751 the function cluster.stats from the package fpc (version 2.2-5). The number of clusters was chosen at the  
752 value at which the lowest distance among patients within clusters (i.e. low value of within-cluster sum of  
753 squares distance) and preserving a high distance among clusters (i.e. high average silhouette width) was  
754 achieved, while still maintaining a comparable number of individuals among the clusters.

### 755 **Linear support vector regression**

756 Linear support vector regression (38) was employed to computationally deconvolute the study's whole  
757 blood samples. Gene expression tables were normalized with DESeq2 and were utilized as the input  
758 mixture file. LM22-subsetted signatures for B cells, T cells, NK cells, monocytes, dendritic cells, eosinophils  
759 and neutrophils were generated as described on <https://cibersort.stanford.edu/tutorial.php>. The algorithm  
760 was subsequently run with 1,000 permutations and the proportions of cell types were visualized with ggplot2  
761 (v3.2.1) (93).

## 762 **CoCena<sup>2</sup>: Construction of Co-expression networks, analysis - automated**

763 To define differences and similarities in transcript expression patterns among the different groups, CoCena<sup>2</sup>  
764 (Construction of co-expression Network Analysis – automated) was performed based on Pearson  
765 correlation. CoCena<sup>2</sup> is a network-based approach to identify clusters of genes that are co-expressed in a  
766 series of observed conditions based on data retrieved from RNA-sequencing. The tool offers a variety of  
767 functions that allow subsequent in-depth analysis of the biological context associated with the found  
768 clusters. As input for the analysis the 10,000 most variable genes were used.

769 To identify genes whose expression patterns are highly similar across all tested samples, pairwise Pearson  
770 correlation coefficients are calculated using the R package Hmisc (v4.1-1). The underlying assumption of  
771 the Pearson correlation to the data is that it is normally distributed, which is a valid assumption to make in  
772 the context of gene expression when looking at expression patterns within different experimental conditions.  
773 The correlation between each pair of genes is the basis for the subsequent network construction. Therefore,  
774 the tool focuses mainly on positively correlated gene pairs, since the rate of confirmation of an edge  
775 representing an association of genes is higher than that of a non-existing association.

776 In order to refine the structure of the upcoming network and to unravel the condition specific signatures, a  
777 correlation cut-off is proposed to mark the minimal correlation a pair of genes must exhibit for their co-  
778 expression to be taken into account. The cut-off is determined based on different criteria:

779 1) Scale-free topology:

780 Gene expression networks have been argued to have a scale-free topology (94), meaning that the majority  
781 of vertices has a low number of adjacent edges, also referred to as the vertex' degree, whereas only very  
782 few vertices have a high degree. The degree distribution of scale-free networks asymptotically follows a  
783 power law. To assess the scale-free topology of a network constructed by a given correlation cut-off, a log-  
784 log plot of the degree distribution is constructed and the R<sup>2</sup>-value of the resulting linear regression is used  
785 to evaluate the scale-free criterion.

786 2) Number of graph components:



787 A graph component is a subset of nodes, such that there is a path from every node within the component  
788 to any other node in that same component but none connecting the nodes to any outside of that component.  
789 Even though there exist functional collections of genes that cooperate to fulfil a common task, these  
790 collections are not expected to be operating independently within the cell. Thus, the cut-off proposal favors  
791 graphs with a small number of components.

792 3) Number of edges:

793 To avoid a highly connected graph with great lack of structure -“hairball”-, the cut-off is chosen such that  
794 the number of edges is minimized while respecting the above-mentioned criteria.

795 A Pearson correlation coefficient cut-off of 0.857 (6,085 nodes and 252,584 edges) was chosen to construct  
796 scale-free networks.

797 The undirected co-expression network is constructed based on the gene pairs which show a higher  
798 correlation in their expression pattern than the set cut-off. A series of network-based clustering algorithms  
799 is available to then identify clusters of strong co-expression within the network. An option “auto” is provided,  
800 which tests the different clustering algorithms and picks the one that achieves the highest modularity score.  
801 Unbiased clustering was performed using the “label propagation” algorithm in igraph (v1.2.1) [The igraph  
802 software package for complex network research] and was repeated 1,000 times. Genes assigned to more  
803 than 5 different clusters during the iterations received no cluster assignment.

804 To assess the expression strength of the found gene clusters in the different studied conditions, the group  
805 fold changes (GFCs) of the conditions are calculated for each gene by calculating the mean expression of  
806 a gene over all samples and then computing the fold change of the mean gene expression within each  
807 condition from the overall mean. The GFCs of all genes within one cluster are then added and divided by  
808 the total number of genes per cluster, resulting in condition-specific GFCs per cluster. Agglomerative  
809 hierarchical clustering was performed by the hclust function (cluster package, version 2.1.0), using a  
810 dissimilarity matrix of samples based on the GFC values of each sample defined with the daisy function for  
811 calculating the Euclidean distances. The number of clusters was set to achieve a low within-cluster sum of  
812 squares distance and a high average silhouette, while preserving a comparable number of individuals within  
813 each cluster. The clinical parameters and the GFCs results are displayed in a heat map where conditions  
814 are clustered by their GFCs revealing similar and opposing patterns (Cluster/Condition heat map).

815 Utilizing the R-package *clusterProfiler*, CoCena<sup>2</sup> automatically analyses the gene clusters with respect to  
816 different kinds of gene set enrichments: The genes within each cluster are scanned for enrichment in KEGG  
817 (95), Hallmark (96), Gene-Ontology terms (97) and Reactome (98). Using the R-package *pcaGoPromoter*  
818 (99) the genes are also analyzed for enrichment of transcription factor binding sites and if the predicted

819 transcription factors are present in the data, their expression profile is visualized to facilitate evaluation of  
820 their possible role.

821 To investigate the interactions between protein-coding and long-non-coding RNAs, we utilized the enricher  
822 function from the clusterProfiler package. We performed an enrichment analysis for lncRNA species, using  
823 the protein-coding genes that belong to the lightgreen cluster as the input gene list and all the network  
824 protein-coding genes as background. The annotation table defining lncRNA to protein-coding RNA was  
825 downloaded from the RNA interactome database RNAInter (100), filtered to only include interactions of  
826 lncRNA detected by the RNA sequencing, had an experimental validation score of at least 0.5 and were  
827 involved in regulating the function of granulocytes (36). Next, to obtain a comprehensive understanding of  
828 the lncRNA that may be relevant for this specific network module, the lncRNA found by the enrichment  
829 analysis with p-value <0.1 were sorted according to the highest number of genes. Thereafter, Spearman  
830 correlation amongst the gene expression of each lncRNA and its corresponding protein-coding RNAs was  
831 performed, and significant protein-coding RNA genes were plotted in a heat map. The CoCena<sup>2</sup> network  
832 was visualized by using the ggplot function from the ggplot2 package. Annotations were generated by  
833 filtering the edges of the network for the 5 top connected transcription factors, epigenetic regulators, and  
834 surface and secretome markers in each cluster. GO enrichment analysis was performed on each cluster  
835 by utilizing the enrichGO function from the clusterProfiler package to assess the overall functionality of the  
836 cluster using the genes of each cluster as the input and all the in the network as background. The top GO  
837 term and top connected genes of each cluster were compiled representing their general characteristic.

### 838 **Granulocyte dataset analysis**

839 Granulocyte raw data was aligned and quantified using STAR (v2.7.3a) and the human reference genome,  
840 GRCh38p13, from the Genome Reference Consortium. Raw counts were imported using  
841 DESeqDataSetFromHTSeqCount function and rlog transformed. DESeq2 was used for the calculation of  
842 normalized counts for each transcript using default parameters. All normalized transcripts with a maximum  
843 over all row mean lower than 10 were excluded resulting in 27,323 present transcripts. Differentially  
844 expressed genes were calculated for the severe vs mild for day 1-14 and 15-28 post 1st symptoms groups)  
845 separately using a p-value cut-off of 0.05, an adjusted p-value (IHW) <0.05 (independent hypothesis  
846 weighting) and a FC of 2. All present transcripts were used as input for principal component analysis. DEGs  
847 were visualized as DE bar plots.

### 848 **Data Integration for Disease Comparison**

849 To describe the differences and similarities between COVID-19 and other diseases, we searched in  
850 databases for genomics data such as Gene Expression Omnibus (GEO) (101) and ArrayExpress (102) [for  
851 studies that fulfill certain criteria: I) having at least 20 samples, II) the disease of study was of relevance  
852 (other infections, such as bacterial and viral, plus diseases that mainly involve immune dysregulation, such

853 as autoimmune disease) and III) library preparation and sequencing technology differ as little as possible  
854 from our COVID-19 protocol. The fastq files of 18 additional studies (588242, GSE101705, GSE107104,  
855 GSE112087, GSE127792, GSE128078, GSE129882, GSE133378, GSE143507, GSE57253, GSE63042,  
856 GSE66573, GSE79362, GSE84076, GSE89403, GSE90081, GSE97590, GSE99992 and the Rhineland  
857 study) were downloaded and aligned with STAR. The counts were imported into R (v3.6.2) and were  
858 modelled for each gene using DESeq2. Merged raw counts were filtered for the genes present in the  
859 COVID-19 co-expression network, ribosomal protein-coding genes and mitochondrial genes were removed,  
860 yielding a total of 5,770 genes and 3,176 samples. To account for differences in sequencing depth across  
861 studies, a quantile normalization was performed on the filtered data. Group fold changes were calculated,  
862 where the grouping variable was set to be the disease status.

863 To explore COVID-19 associated expression of genes within the integrated dataset, the data was  
864 intersected with the gene modules previously retrieved from the COVID-19 CoCena<sup>2</sup> network, the mean  
865 group-fold-changes were determined per cluster and condition and visualized in a heat map.  
866 The modules were analyzed for enriched immune cell markers as provided by CIBERSORT and BD  
867 Rhapsody and those that showed neutrophil enrichment were screened for genes representative of different  
868 neutrophil subtypes as recently described (42).

## 869 **Enrichment of signature from scRNA data of granulocytes**

870 The signatures of different neutrophil states in COVID-19 as previously described (42) were enriched for  
871 the different clusters from CoCena<sup>2</sup>.

872 To get a more fine-grained differentiation of the specific neutrophil states for figure 3, the authors kindly  
873 provided additional signatures from the scRNA dataset using a Wilcoxon rank sum test for differential gene  
874 expression implemented in Seurat. Genes had to be expressed in >10% of the cells of a cluster, exceed a  
875 logarithmic threshold >0.1 and to have >5% difference in the minimum detection between two clusters. The  
876 following additional comparisons were performed: 8 and 9 (pre- and immature neutrophils combined) VS  
877 the rest, 1,3,4,6 (neutrophil states from control patients) VS the rest. To get unique signature genes for  
878 clusters 0, 2 and 5 (COVID-19-specific clusters) we took the following approach for each cluster: 1)  
879 Calculate DEG for cluster 0 VS all other clusters. 2) Calculate DEG for cluster 0 vs 2&5. 3) Take intersection  
880 of these two calculations. 4) Remove genes that occur in more than one of these intersections of cluster  
881 0,2 or 5.

## 882 **Gene set enrichment analysis (GSVA)**

883 The GSVA R package (v1.34.0) (103) was used to test the enrichment of neutrophil signatures (42) in the  
884 normalized gene expression table. The *gsva* method was used for the run and data were visualized in a  
885 heat map with the *pheatmap* (v1.0.12) package.

## 886 Overview of drugs

887 An overview of currently used, recommended or investigated drugs for treatment of COVID-19 patients was  
888 compiled from drug lists and lists of drugs in clinical trials downloaded from [https://www.drugbank.ca/covid-](https://www.drugbank.ca/covid-19)  
889 [19](https://www.drugbank.ca/covid-19), <https://www.pharmgkb.org/page/COVID> and <https://clinicaltrials.gov/ct2/results?cond=COVID-19> (last  
890 update: 2020-06-05). Classification of the drugs was performed based on the ATC code, as well as  
891 additional research on the drugs action. Drug target genes were identified using the DrugBank database  
892 (104) (Table S6). The number drugs currently recommended or investigated, as well as the number of  
893 clinical trials within the respective drug classes were visualized using the ggplot2 package (105, 106). The  
894 target genes of the drugs currently recommended or investigated with a minimum frequency of 4 were  
895 visualized in a word cloud using the wordcloud package (version 2.6).

896

## 897 Drug prediction

898 To identify drugs, which reverse the gene expression signature observed in the comparisons of the COVID-  
899 19-specific clusters compared to the control cluster, the drug prediction databases iLINCS  
900 (<http://www.ilincs.org/ilincs/>) and CLUE (<https://clue.io/>) were accessed. As input for the drug prediction the  
901 top 1000 (iLINCS) or the top 100 (CLUE) DEGs were used. Drugs reversing the COVID-19 gene expression  
902 signature (defined by a negative score) were pooled together with drugs under investigation in current  
903 literature, resulting in a list of 940 unique drugs. Using the iLINCS API ([https://github.com/uc-](https://github.com/uc-bd2k/ilincsAPI/blob/master/usingIlincsApis.Rmd)  
904 [bd2k/ilincsAPI/blob/master/usingIlincsApis.Rmd](https://github.com/uc-bd2k/ilincsAPI/blob/master/usingIlincsApis.Rmd)), every gene expression signature from each drug listed in  
905 the signature libraries iLINCS chemical perturbagens (LINCSCP), iLINCS targeted proteomics signatures  
906 (LINCSTP), Disease-related signatures (GDS), Connectivity Map signatures (CMAP), DrugMatrix  
907 signatures (DM), Transcriptional signatures from EBI Expression Atlas (EBI), Cancer therapeutics response  
908 signatures (CTRS) and Pharmacogenomics transcriptional signatures (PG) were downloaded. Labelling  
909 was performed in the following principle: “drug name”\_”database”\_”database ID”. Signatures were ordered  
910 by fold change and only the top 300 genes were used. This resulted in a total of 62,897 unique drug  
911 signatures each with an up- and down-regulated set. Subsequently, GSEA (107) was performed on the  
912 sequencing data for every up- and down-regulated set for each drug and each cluster comparison. The  
913 resulting normalized enrichment scores (NES) were used to calculate the delta NES for each drug, defined  
914 as  $\Delta NES = NES(\text{down}) - NES(\text{up})$ , ergo the difference of the NES from the downregulated set and the  
915 NES from the upregulated set of each respective drug. These  $\Delta NES$  values were then k-mean clustered  
916 (k=40). The clusters showing the highest  $\Delta NES$  values for all comparisons and the cluster showing only  
917 high  $\Delta NES$  in the comparison G1vsG6 (most severe) were chosen and selected ones of the uniquely  
918 present drugs shown. The leading edge genes of the downregulation signatures of these drugs for the

919 G1vsG6 comparison were examined and the frequency was counted. Recurring target genes were plotted  
920 on the CoCena<sup>2</sup> network.

921 Patterns of differential gene expression of genes targeted by drugs which are currently approved or under  
922 investigation for the treatment of COVID-19 patients were visualized using ggplot2. To this end, target  
923 genes of each drug and their first degree neighbors were extracted from several databases and the gene  
924 co-expression networks, respectively. Regulation patterns of expression of these genes in different COVID-  
925 19 patient groups, as compared to the control group, were classified as up-/downregulated or not significant  
926 (n.s.) when pairwise comparisons of gene expression of COVID-19 patients and controls were not  
927 statistically significant. The same methodology was applied to genes not included in the drug-target list to  
928 identify genes which are not targeted by current drugs but could be potentially targeted by newly identified  
929 drugs.

930

## 931 **CONTACT FOR REAGENT AND RESOURCE SHARING**

932 For further information and requests for resources and reagents should be directed to and will be fulfilled  
933 by the lead contact, Dr. Thomas Ulas ([t.ulas@uni-bonn.de](mailto:t.ulas@uni-bonn.de)).

934

## 935 **DATA AND SOFTWARE AVAILABILITY**

936 Data Availability

937 The data that support the findings of this study, including transcriptome data from 60 patients at multiple  
938 time points who granted informed consent to share such data, are made available at the European  
939 Genome-Phenome Archive (EGA) under accession number EGAS00001004503, which is hosted by the  
940 EBI and the CRG. The Rhineland Study's dataset is not publicly available because of data protection  
941 regulations. Access to data can be provided to scientists in accordance with the Rhineland Study's Data  
942 Use and Access Policy. Requests for further information or to access the Rhineland Study's dataset should  
943 be directed to [RS-DUAC@dzne.de](mailto:RS-DUAC@dzne.de). In addition to data deposition on EGA, we provide an interactive  
944 platform for data inspection and analysis via FASTGenomics ([fastgenomics.org](http://fastgenomics.org)). The FASTGenomics  
945 platform also provides normalized count tables of the datasets generated in this study. Materials, code, and  
946 data are available from the corresponding author upon reasonable request. CoCena<sup>2</sup> is also available under  
947 <https://github.com/Ulas-lab/CoCena2>.

## 948 REFERENCES

- 949 1. N. D. Grubaugh, M. E. Petrone, E. C. Holmes, We shouldn't worry when a virus mutates during  
950 disease outbreaks. *Nat. Microbiol.* **5** (2020), pp. 529–530.
- 951 2. J. R. Fauver *et al.*, *Cell*. **181** (2020), doi:10.1016/j.cell.2020.04.021.
- 952 3. P. Zhou *et al.*, *Nature*. **579**, 270–273 (2020).
- 953 4. C. Brignola *et al.*, *J. Clin. Gastroenterol.* **10**, 631–634 (1988).
- 954 5. W. Guan *et al.*, *N. Engl. J. Med.* **382**, 1708–1720 (2020).
- 955 6. C. Huang *et al.*, *Lancet*. **395**, 497–506 (2020).
- 956 7. F. Zhou *et al.*, *Lancet*. **395**, 1054–1062 (2020).
- 957 8. D. Wang *et al.*, *JAMA - J. Am. Med. Assoc.* **323**, 1061–1069 (2020).
- 958 9. E. Z. Ong *et al.*, *Cell Host Microbe*. **27** (2020), doi:10.1016/j.chom.2020.03.021.
- 959 10. B. Wang, R. Li, Z. Lu, Y. Huang, *Aging (Albany. NY)*. **12**, 6049–6057 (2020).
- 960 11. W. J. Guan *et al.*, *Eur. Respir. J.* **55** (2020), doi:10.1183/13993003.00547-2020.
- 961 12. R. T. Gandhi, J. B. Lynch, C. del Rio, *N. Engl. J. Med.* (2020), doi:10.1056/nejmcp2009249.
- 962 13. S. A. Dugger, A. Platt, D. B. Goldstein, Drug development in the era of precision medicine. *Nat.*  
963 *Rev. Drug Discov.* **17** (2018), pp. 183–196.
- 964 14. A. Zumla *et al.*, Towards host-directed therapies for tuberculosis. *Nat. Rev. Drug Discov.* **14**  
965 (2015), pp. 511–512.
- 966 15. A. Mullard, Coordinating the COVID-19 pipeline. *Nat. Rev. Drug Discov.* **19** (2020), p. 298.
- 967 16. H. Ledford, *Nature*. **581** (2020), doi:10.1038/d41586-020-01367-9.
- 968 17. D. A. Berlin, R. M. Gulick, F. J. Martinez, *N. Engl. J. Med.* (2020), doi:10.1056/nejmcp2009575.
- 969 18. G. Dimopoulos *et al.*, *Cell Host Microbe* (2020), doi:10.1016/j.chom.2020.05.007.
- 970 19. Y. Jamilloux *et al.*, Should we stimulate or suppress immune responses in COVID-19? Cytokine  
971 and anti-cytokine interventions. *Autoimmun. Rev.* **19** (2020), , doi:10.1016/j.autrev.2020.102567.
- 972 20. D. E. Zak *et al.*, *Lancet*. **387**, 2312–2322 (2016).
- 973 21. E. G. Thompson *et al.*, *Tuberculosis*. **107**, 48–58 (2017).
- 974 22. S. Leong *et al.*, *Tuberculosis*. **109**, 41–51 (2018).
- 975 23. S. Verma *et al.*, *BMC Infect. Dis.* **18** (2018), doi:10.1186/s12879-018-3127-4.
- 976 24. E. L. Tsalik *et al.*, *Genome Med.* **6** (2014), doi:10.1186/s13073-014-0111-5.
- 977 25. A. Rechten *et al.*, *Cell Rep.* **20**, 2251–2261 (2017).
- 978 26. D. Michlmayr *et al.*, *Mol. Syst. Biol.* **14** (2018), doi:10.15252/msb.20177862.
- 979 27. J. A. Hill *et al.*, *J. Virol.* **93** (2018), doi:10.1128/jvi.01419-18.
- 980 28. E. Bartholomeus *et al.*, *J. Transl. Med.* **17** (2019), doi:10.1186/s12967-019-2037-6.
- 981 29. X. Yang *et al.*, *Lancet Respir. Med.* **8**, 475–481 (2020).
- 982 30. G. Chen *et al.*, *J. Clin. Invest.* **130**, 2620–2629 (2020).

- 983 31. E. J. Giamarellos-Bourboulis *et al.*, *Cell Host Microbe* (2020), doi:10.1016/j.chom.2020.04.009.
- 984 32. J. Hadjadj *et al.*, *medRxiv*, in press, doi:10.1101/2020.04.19.20068015.
- 985 33. M. Merad, J. C. Martin, Pathological inflammation in patients with COVID-19: a key role for  
986 monocytes and macrophages. *Nat. Rev. Immunol.* **20** (2020), , doi:10.1038/s41577-020-0331-4.
- 987 34. P. Lalezari, G. B. Murphy, F. H. Allen, *J. Clin. Invest.* **50**, 1108–1115 (1971).
- 988 35. R. Grieshaber-Bouyer, P. A. Nigrovic, Neutrophil heterogeneity as therapeutic opportunity in  
989 immune-mediated disease. *Front. Immunol.* **10** (2019), , doi:10.3389/fimmu.2019.00346.
- 990 36. X. Tian, J. Tian, X. Tang, J. Ma, S. Wang, *J. Hematol. Oncol.* **9** (2016), doi:10.1186/s13045-016-  
991 0333-7.
- 992 37. Y. Zhang *et al.*, *Biomed. Pharmacother.* **94**, 644–651 (2017).
- 993 38. A. M. Newman *et al.*, *Nat. Methods.* **12**, 453–457 (2015).
- 994 39. W. Shang *et al.*, *J. Med. Virol.* (2020), doi:10.1002/jmv.26031.
- 995 40. X. Yan *et al.*, *J. Med. Virol.* (2020), doi:10.1002/jmv.26061.
- 996 41. C. Wenham, J. Smith, R. Morgan, COVID-19: the gendered impacts of the outbreak. *Lancet.* **395**  
997 (2020), pp. 846–848.
- 998 42. J. Schulte-Schrepping *et al.*, *medRxiv*, in press, doi:10.1101/2020.06.03.20119818.
- 999 43. N. Romberg *et al.*, *Nat. Genet.* **46**, 1135–1139 (2014).
- 1000 44. S. W. Canna *et al.*, *Nat. Genet.* **46**, 1140–1146 (2014).
- 1001 45. D. Michlmayr *et al.*, *Cell Rep.* **31** (2020), doi:10.1016/j.celrep.2020.107569.
- 1002 46. L. S. de Araujo *et al.*, *Front. Microbiol.* **7** (2016), doi:10.3389/fmicb.2016.01586.
- 1003 47. W. A. Figgett *et al.*, *Clin. Transl. Immunol.* **8** (2019), doi:10.1002/cti2.1093.
- 1004 48. K. Shchetynsky *et al.*, *Arthritis Res. Ther.* **19** (2017), doi:10.1186/s13075-017-1220-5.
- 1005 49. R. D. Gray *et al.*, *J. Inflamm. (United Kingdom).* **10** (2013), doi:10.1186/1476-9255-10-12.
- 1006 50. A. S. Rohrbach, D. J. Slade, P. R. Thompson, K. A. Mowen, Activation of PAD4 in NET formation.  
1007 *Front. Immunol.* **3** (2012), , doi:10.3389/fimmu.2012.00360.
- 1008 51. A. Carestia *et al.*, *J. Leukoc. Biol.* **99**, 153–162 (2016).
- 1009 52. N. L. Denning, M. Aziz, S. D. Gurien, P. Wang, Damps and nets in sepsis. *Front. Immunol.* **10**  
1010 (2019), , doi:10.3389/fimmu.2019.02536.
- 1011 53. B. McDonald *et al.*, *Blood.* **129**, 1357–1367 (2017).
- 1012 54. P. Jha, H. Das, *Int. J. Mol. Sci.* **18** (2017), doi:10.3390/ijms18112383.
- 1013 55. T. Németh, M. Sperandio, A. Mócsai, Neutrophils as emerging therapeutic targets. *Nat. Rev. Drug*  
1014 *Discov.* **19** (2020), pp. 253–275.
- 1015 56. M. Pilarczyk *et al.*, *bioRxiv*, 826271 (2019).
- 1016 57. S. M. Corsello *et al.*, The Drug Repurposing Hub: A next-generation drug library and information  
1017 resource. *Nat. Med.* **23** (2017), pp. 405–408.
- 1018 58. M. Baumann, C. T. N. Pham, C. Benarafa, *Blood.* **121**, 3900–3907 (2013).
- 1019 59. A. Torriglia, E. Martin, I. Jaadane, The hidden side of SERPINB1/Leukocyte Elastase Inhibitor.  
1020 *Semin. Cell Dev. Biol.* **62** (2017), pp. 178–186.


- 1021 60. L. Duplomb *et al.*, *J. Mol. Med.* **97**, 633–645 (2019).
- 1022 61. “Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe  
1023 respiratory complications of COVID-19” (2020), (available at  
1024 [https://www.recoverytrial.net/files/recovery\\_dexamethasone\\_statement\\_160620\\_v2final.pdf](https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf)).
- 1025 62. M. Fuortes, M. Melchior, H. Han, G. J. Lyon, C. Nathan, *J. Clin. Invest.* **104**, 327–335 (1999).
- 1026 63. L. A. Kamen, J. Schlessinger, C. A. Lowell, *J. Immunol.* **186**, 1656–1665 (2011).
- 1027 64. W. C. Koff, M. A. Williams, *N. Engl. J. Med.* (2020), doi:10.1056/nejmp2006761.
- 1028 65. L. Bao *et al.*, *Nature* (2020), doi:10.1038/s41586-020-2312-y.
- 1029 66. N. Lee, A. McGeer, The starting line for COVID-19 vaccine development. *Lancet.* **395** (2020), pp.  
1030 1815–1816.
- 1031 67. N. Lurie, M. Saville, R. Hatchett, J. Halton, Developing covid-19 vaccines at pandemic speed. *N.*  
1032 *Engl. J. Med.* **382** (2020), pp. 1969–1973.
- 1033 68. E. Callaway, *Nature.* **580**, 576–577 (2020).
- 1034 69. K. Subbarao, S. Mahanty, *Immunity.* **52**, 905–909 (2020).
- 1035 70. N. Vabret *et al.*, *Immunity* (2020), doi:10.1016/j.immuni.2020.05.002.
- 1036 71. Y. H. Huang, M. H. Lo, X. Y. Cai, S. F. Liu, H. C. Kuo, *Pediatr. Rheumatol.* **17** (2019),  
1037 doi:10.1186/s12969-019-0315-8.
- 1038 72. J. Toubiana *et al.*, *BMJ.* **369**, m2094 (2020).
- 1039 73. R. M. Viner, E. Whittaker, Kawasaki-like disease: emerging complication during the COVID-19  
1040 pandemic. *Lancet.* **395** (2020), , doi:10.1016/S0140-6736(20)31129-6.
- 1041 74. G. Ronconi *et al.*, *J. Biol. Regul. Homeost. Agents.* **34** (2020), doi:10.23812/EDITORIAL-  
1042 RONCONI-E-59.
- 1043 75. H. Al-Samkari *et al.*, *Blood* (2020), doi:10.1182/blood.2020006520.
- 1044 76. F. A. Klok *et al.*, *Thromb. Res.* **191** (2020), doi:10.1016/j.thromres.2020.04.013.
- 1045 77. T. J. Oxley *et al.*, *N. Engl. J. Med.* **382**, e60 (2020).
- 1046 78. C. Creel-Bulos *et al.*, Acute cor pulmonale in critically ill patients with covid-19. *N. Engl. J. Med.*  
1047 **382** (2020), , doi:10.1056/NEJMc2010459.
- 1048 79. J. W. Tyner *et al.*, *Nature.* **562**, 526–531 (2018).
- 1049 80. F. Rambow *et al.*, *Cell.* **174**, 843-855.e19 (2018).
- 1050 81. Z. Qiu *et al.*, *Cancer Cell.* **36**, 179-193.e11 (2019).
- 1051 82. A. B. Keenan *et al.*, The Library of Integrated Network-Based Cellular Signatures NIH Program:  
1052 System-Level Cataloging of Human Cells Response to Perturbations. *Cell Syst.* **6** (2018), pp. 13–  
1053 24.
- 1054 83. A. Subramanian *et al.*, *Cell.* **171**, 1437-1452.e17 (2017).
- 1055 84. Y. Zhou *et al.*, *Cell Discov.* **6** (2020), doi:10.1038/s41421-020-0153-3.
- 1056 85. E. P. Scully, J. Haverfield, R. L. Ursin, C. Tannenbaum, S. L. Klein, Considering how biological  
1057 sex impacts immune responses and COVID-19 outcomes. *Nat. Rev. Immunol.* (2020), ,  
1058 doi:10.1038/s41577-020-0348-8.
- 1059 86. J. Shi *et al.*, *Science.* **368**, 1016–1020 (2020).



- 1060 87. A. Dobin *et al.*, STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics*. **29** (2013), pp. 15–21.
- 1061 88. M. I. Love, W. Huber, S. Anders, *Genome Biol.* **15** (2014), doi:10.1186/s13059-014-0550-8.
- 1062 89. A. Liberzon *et al.*, *Bioinformatics*. **27**, 1739–40 (2011).
- 1063 90. G. Yu, L. G. Wang, Y. Han, Q. Y. He, *Omi. A J. Integr. Biol.* **16**, 284–287 (2012).
- 1064 91. D. L. Fulton *et al.*, *Genome Biol.* **10** (2009), doi:10.1186/gb-2009-10-3-r29.
- 1065 92. M. Uhlén *et al.*, *Science (80- )*. **347** (2015), doi:10.1126/science.1260419.
- 1066 93. K. Ito, D. Murphy, *CPT Pharmacometrics Syst. Pharmacol.* **2** (2013), doi:10.1038/psp.2013.56.
- 1067 94. P. Aloy, R. B. Russell, *EMBO Rep.* **5**, 349–350 (2004).
- 1068 95. M. Kanehisa, S. Goto, *Nucleic Acids Res.* **28**, 27–30 (2000).
- 1069 96. A. Liberzon *et al.*, *Cell Syst.* **1**, 417–425 (2015).
- 1070 97. Gene Ontology Consortium, *Nucleic Acids Res.* **43**, D1049-56 (2015).
- 1071 98. A. Fabregat *et al.*, *Nucleic Acids Res.* **46**, D649–D655 (2018).
- 1072 99. M. Hansen *et al.*, *PLoS One.* **7** (2012), doi:10.1371/journal.pone.0032394.
- 1073 100. Y. Lin *et al.*, *Nucleic Acids Res.* **48**, D189–D197 (2020).
- 1074 101. E. Clough, T. Barrett, in *Methods in Molecular Biology* (Humana Press Inc., 2016), vol. 1418, pp.  
1075 93–110.
- 1076 102. A. Athar *et al.*, *Nucleic Acids Res.* **47**, D711–D715 (2019).
- 1077 103. S. Hänzelmann, R. Castelo, J. Guinney, *BMC Bioinformatics.* **14** (2013), doi:10.1186/1471-2105-  
1078 14-7.
- 1079 104. D. S. Wishart *et al.*, *Nucleic Acids Res.* **46**, D1074–D1082 (2018).
- 1080 105. H. Wickham, *Ggplot2: elegant graphics for data analysis* (Springer, 2009).
- 1081 106. N. Neth, H.; Gradwohl, unkn: Graphical elements of the University of Konstanz’s corporate  
1082 design. *Soc. Psychol. Decis. Sci.* (2019), (available at [https://www.spds.uni-](https://www.spds.uni-konstanz.de/publication-page/unikn-graphical-elements-university-konstanzs-corporate-design)  
1083 [konstanz.de/publication-page/unikn-graphical-elements-university-konstanzs-corporate-design](https://www.spds.uni-konstanz.de/publication-page/unikn-graphical-elements-university-konstanzs-corporate-design)).
- 1084 107. G. Korotkevich, V. Sukhov, A. Sergushichev, *bioRxiv*, 060012 (2019).

## 1085 FIGURES

# Figure 1



1087 *Figure 1 – Whole blood transcriptomes reveal diversity of COVID-19 patients not explained by*  
1088 *disease severity*

1089 **(a)** Schematic workflow for analysis of whole blood transcriptome data.

1090 **(b)** PCA plot depicting relationship of all samples based on dynamic gene expression of all genes  
1091 comparing COVID-19 and control samples.

1092 **(c)** Number of significantly upregulated (red) and downregulated (blue) genes ( $FC > |2|$ , FDR-adj. p-value  
1093  $< 0.05$ ) comparing COVID-19 and control samples.

1094 **(d)** Volcano plot depicting fold changes (FC) and FDR-adjusted p-values comparing COVID-19 and control  
1095 samples. Differentially expressed up- (red) and downregulated genes (blue) are shown and selected genes  
1096 are highlighted.

1097 **(e)** Plot of top 10 most enriched GO terms for significantly up- and downregulated genes, showing ratio of  
1098 significantly regulated genes within enriched GO terms (GeneRatio).


1099 **(f)** PCA plot depicting relationship of all samples based on dynamic gene expression of all genes comparing  
1100 mild and severe COVID-19 as well as control samples.

1101 **(g)** Number of significantly upregulated (red) and downregulated (blue) genes ( $FC > |2|$ , FDR-adj. p-value  $<$   
1102  $0.05$ ) comparing mild and severe COVID-19 as well as control samples.

1103 **(h)** Volcano plot depicting fold changes and FDR-adjusted p-values comparing mild and severe COVID-19  
1104 as well as control samples. Differentially expressed up- (red) and downregulated genes (blue) are shown  
1105 and selected genes are highlighted.

1106 **(i)** Hierarchical clustering map of 25% most variable genes between control patients, COVID-19 mild or  
1107 severe patients, with additional annotation of disease outcome, hierarchical agglomerative clustering of  
1108 clinical parameters COVID-19, and the groups defined by agglomerative clustering.

## Supplemental Figure 1 - related to Figure 1



1110 *Figure S1 – related to Figure 1*

1111 **(a-b)** Volcano plots depicting fold changes and FDR-adjusted p-values comparing severe **(a)** or mild **(b)**  
1112 COVID-19 patients vs. controls. Differentially expressed up- (red) and downregulated genes (blue) are  
1113 shown and selected genes are highlighted.

1114 **(c)** Plot of top 10 most enriched GO terms for significantly up- and downregulated genes. Ratios of  
1115 significantly regulated genes within enriched GO terms (GeneRatio) are shown for the comparisons  
1116 between mild or severe COVID-19 patients and controls as well as between ‘mild’ and ‘severe’ COVID-19  
1117 patients.


1118 **(d)** Heat map of group mean gene expression values from the top 20 most variant transcription factors,  
1119 epigenetic regulators, surface and secreted proteins.

1120 **(e)** Heat map of the linear model adjusted r-square that includes each clinical parameter with PC1. Clinical  
1121 parameters with r-adjusted square  $\geq 0.1$  were used for agglomerative clustering of COVID-19 patients.

1122 **(f)** Plots for agglomerative clustering statistics: within cluster sum of squares and high average silhouette  
1123 width scores.

1124 **(g)** Heat map presenting summary statistics of the clinical parameters used for the clustering across clinical  
1125 agglomerative clusters 1-5.

## Figure 2



1127 *Figure 2 – Co-expression analysis discloses COVID-19 subgroups with distinct molecular*  
1128 *signatures*

1129 **(a)** Schematic overview of the analysis performed on the whole blood samples.

1130 **(b)** Alluvium plot visualizing the distribution of the samples according to different grouping; disease status,  
1131 severity and data-driven sample groups.

1132 **(c)** Group fold change heat map and hierarchical clustering for the six data-driven sample groups and the  
1133 gene modules identified byCoCena<sup>2</sup> analysis.

1134 **(d)** Functional enrichment of CoCena<sup>2</sup>-derived modules using the Hallmark gene set database. Selected  
1135 top terms were visualized.

1136 **(e)** Functional enrichment of CoCena<sup>2</sup> module lightgreen using GO gene set database. Top 5 terms were  
1137 visualized.


1138 **(f)** Heat map presenting the normalized expression values of the lncRNA *CYTOR*, and protein coding RNAs  
1139 *PIK3CB* and *VIM* from the lightgreen CoCena<sup>2</sup> module.

1140 **(g)** Neutrophil-lymphocyte ratio plot after cell type deconvolution at lineage level.

1141 **(h)** Neutrophil-lymphocyte ratio across the six data-driven sample groups. Box plots show median with  
1142 variance, with lower and upper hinges representing the 25<sup>th</sup> and 75<sup>th</sup> percentile, respectively.



## Supplemental Figure 2 - related to Figure 2



1143

1144 *Figure S2 – related to Figure 2*

1145 **(a)** Group fold change (GFC) heat map and hierarchical clustering for each sample and the gene modules  
1146 identified by CoCena<sup>2</sup> analysis.

1147 **(b)** Agglomerative hierarchical clustering of the samples according to the GFC. Top plots present the  
1148 clustering statistics (within cluster sum of squares and high average silhouette width scores) used for the  
1149 generation of the six data-driven CoCena<sup>2</sup> sample groups G1-G6, which are plotted in the dendrogram plot.

1150 **(c)** Heat map presenting summary statistics of clinical parameters for COVID-19 patients grouped according  
1151 to the CoCena<sup>2</sup> sample groups G1-G5 Presented are scaled values of the mean value of the parameters  
1152 age/blood cell counts/SOFA score/Pneumonia Index/Charlson score, and prevalence of the  
1153 comorbidity/death (outcome)/male (sex)/immune classification (intermediate/dysregulation/MAS).  
1154 Statistical differences were estimated among the groups via the one-sided Anova test or Fisher test, for  
1155 numeric or categorical values respectively. (\*, \*\* p-value < 0.05, 0.01 respectively)

1156 **(d)** PCA plot depicting relationship of all samples based on dynamic gene expression of all genes. Coloring  
1157 based on the six data-driven CoCena<sup>2</sup> sample groups G1-G6.


1158 **(e)** Cibersort cell type deconvolution at cell subset level. Grouping based on the six data-driven CoCena<sup>2</sup>  
1159 sample groups G1-G6.

1160 **(f)** Flow cytometry analysis, number of lymphocytes (upper) and neutrophils (lower) per  $\mu$ l of blood.  
1161 Grouping based on the six data-driven CoCena<sup>2</sup> sample groups G1-G6.

1162 **(g)** Heat map of DE and top 20 most variable transcription factors, epigenetic regulators, surface and &  
1163 secreted proteins.

## Supplemental Figure 3 - related to Figure 2

a




1165 *Figure S3 – related to Figure 2*

1166 **(a)** Visualization of the COVID-19 CoCena<sup>2</sup> network. Nodes are genes and edges represent co-expressed  
1167 genes. Additional module information is displayed by module-colored labels. Labels include information  
1168 about top-connected transcription factors (TFs), epigenetic regulators, surface & secreted markers as well  
1169 as representative Hallmark terms.

## Supplemental Figure 4 - related to Figure 2


**a**

Co-expression heatmap per sample based on modules Fig 2C




**b**

Agglomerative hierarchical clustering of CoCena<sup>2</sup> network



**c**

Co-expression heatmap per group based on modules Fig 2C



1170


1171 *Figure S4 – related to Figure 2*

1172 **(a)** Heat map of mean group fold changes (GFCs) of the CoCena<sup>2</sup> whole blood modules in the second  
1173 COVID-19 cohort for each sample. Patients are clusters by the mean GFC module expression. Severity  
1174 patterns found in the whole blood CoCena<sup>2</sup> network were identified and patients groups were labeled  
1175 accordingly (G1-G6).

1176 **(b)** Agglomerative hierarchical clustering of the samples according to the GFC. Top plots present the  
1177 clustering statistics (within cluster sum of squares and high average silhouette width scores) used for the  
1178 generation of the six data-driven CoCena<sup>2</sup> sample groups G1-G6, which are plotted in the dendrogram plot.

1179 **(c)** GFC heat map and hierarchical clustering for the four identified sample groups and the gene modules  
1180 identified with CoCena<sup>2</sup> analysis.

## Figure 3



1182 *Figure 3 – Granulocytes from severe COVID-19 patients show a simultaneous increase in*  
1183 *inflammatory and suppressive signatures*

1184 **(a)** Schema of sample processing and analysis.

1185 **(b)** PCA of all genes within the dataset mapped by COVID-19 severity status.

1186 **(c)** Bar plot of DEGs between severe and mild COVID-19 patients at day 1-14 (left) and day 15-28 (right)  
1187 (FC>|2|, FDR-adj. p-value <0.05).

1188 **(d)** Boxplot of *CD177* (left) and *S100A6* (right) in mild and severe COVID-19 patients at day 1-14 and 15-  
1189 28.

1190 **(e)** Mean of group fold changes (GFCs) of the modules maroon, pink and lightgreen in the granulocyte  
1191 samples over time. Patients are grouped according to severity mild (top) and severe (bottom). Samples are  
1192 ordered by the days after disease onset. Maroon, pink and lightgreen lines represent the overall mean of  
1193 GFCs in the mild patient group.

1194 **(f)** Heat map of mean expression of 24 markers in mild (top) and severe (bottom) patients ordered by days  
1195 after disease onset bins (day 1-14, 15-28 and 29-46).


1196 **(g)** Heat map of mean GFCs of the CoCena<sup>2</sup> whole blood modules in the granulocyte samples from each  
1197 individual patient. Patients are clusters by the mean GFC module expression. Severity patterns found in  
1198 the whole blood CoCena<sup>2</sup> network were identified and patients groups were assigned accordingly (G1-G6).  
1199 Patients with a distinct GFC expression pattern were labeled as G7.

1200 **(h)** Box plot of *CD177* expression in granulocytes grouped by G1-G7.

1201 **(i)** Box plot of *CD177* expression in whole blood grouped by G1-G6.



## Supplemental Figure 5 - related to Figure 3



1202  
1203

1204 *Figure S5 – related to Figure 3*

1205 (a) Cibersort computational deconvolution of the 59 granulocyte samples used in Figure 3. The LM22  
1206 reference signature was used.

1207 (b) Functional enrichment analysis of the DEGs between severe and mild COVID-19 patients by GOEA.


1208 (c) CoCena<sup>2</sup> whole blood module genes filtered for severe vs mild COVID-19 DEGs. Intersection of modules  
1209 with DEGs are shown in opaque bars, filtered network module genes are shown in transparent bars.

1210 (d) GSVA of single-cell neutrophil signatures (42). Samples are ordered by COVID-19 severity status and  
1211 days after disease onset.

1212 (e) Box plots of *ARG1*, *CD274*, *NLRC4* and *S100A6* in granulocytes grouped by G1-G7.

1213 (f) Box plot of *ARG1*, *CD274*, *NLRC4* and *S100A6* in whole blood grouped by G1-G6.

## Figure 4



1215 *Figure 4 – Integration with signatures from other diseases reveals COVID-19-specific*  
1216 *characteristics*


1217 **(a)** Schema of analysis of the integrated dataset. The integrated dataset was analyzed with regard to  
1218 expression patterns of the clusters previously identified in the whole blood COVID-19-specific co-  
1219 expression network.

1220  
1221 **(b)** Heat map of mean group fold changes of CoCena<sup>2</sup> module comparison between COVID-19 and other  
1222 diseases. From left to right, the diseases are ordered by category (COVID-19, viral infections, bacterial  
1223 infections and others). On the right side of the heat map, the first box plot shows the enriched immune cell  
1224 markers in each module. The second box plot shows the enrichment of genes upregulated in specific  
1225 neutrophil subtypes based on cross-referencing with single-cell data (42). Both box plots show enriched  
1226 cell types in percent of total hits, absolute hits with respect to cluster size are stated aside.

1227  
1228 **(c)** Gene set variation analysis was conducted for every single patient based on Hallmark gene sets as  
1229 shown in Fig. 2D. The result was standardized to retrieve the z-scores, a disease mean was calculated and  
1230 displayed as a dot plot with size and color correlating to the z-score. The labels on the x-axis are the same  
1231 as in **(b)**.

## Supplemental Figure 6 - related to Figure 4

a




1232  
1233  
1234

1235

1236 *Figure S6 – related to Figure 4*

1237 **(a)** Overview of the composition of the integrated dataset comprising 2,817 samples: 39 COVID-19 samples  
1238 and 2,778 other conditions and controls.

Figure 5



1240 *Figure 5 – Patient subgroup-specific signatures can be used to predict potential drug targets*

- 1241 **(a)** Overview of drugs currently used, investigated or recommended for the treatment of COVID-19 patients.  
1242 The inner circle represents the number of drugs for the representative drug categories, the outer circle  
1243 represents the number of clinical trials of drugs for the respective drug categories.
- 1244 **(b)** Visualization of genes targeted by drugs approved or undergoing trial for the treatment of COVID-19  
1245 patients included in the whole blood co-expression network. Numbers of such genes from each module are  
1246 designated on the right of the panel. Genes are represented as hexagons and colored by the expression  
1247 fold change between COVID-19 patient severity group (G1-G5) and the control group (G6) (upregulated:  
1248 red, downregulated: blue, not regulated: grey).
- 1249 **(c)** Drug predictions based on  $\Delta$ NES score of drug signatures in regard to diseased patient group-specific  
1250 gene expression patterns (G1-5 vs G6). Signatures were clustered by k-means clustering. A high  $\Delta$ NES  
1251 score accounts for drug signatures which counteract the gene expression of the patient group they are  
1252 compared to. Drug signatures with a negative  $\Delta$ NES score induce a gene expression pattern similar to the  
1253 input. The number of signatures within a cluster determines its size.
- 1254 **(d)** Display of selected drug signatures from k-means cluster 5 from **(C)** showing the highest  $\Delta$ NES score  
1255 in the most severe COVID-19 patient group G1 and the least effect in patient group G4.
- 1256 **(e)** Visualization of recurring target genes in the G1 vs G6 comparison of cluster 5 signatures and their  
1257 frequency mapped onto the CoCena<sup>2</sup> network.





1259 *Figure S7 – related to Figure 5*

1260 **(a)** Word cloud of the target genes of drugs currently investigated for the treatment of COVID-19 patients.  
1261 Increasing frequency is represented by increasing size with min. frequency = 41 and max. frequency = 97.

1262 **(b)** Schematic workflow of the drug prediction analysis. Drug signatures were collected using the platforms  
1263 iLINCS and CLUE. Signatures were selected by highest counteracting  $\Delta$ NES score and combined with  
1264 signatures of drugs under investigation from the literature.

1265 **(c)** Differentially expressed genes ( $FC > |2|$ , FDR-adj. p-value  $< 0.05$ ) of comparisons between groups G1-5  
1266 vs G6. Vertical bar plots indicate the number of group-specific differentially expressed genes (DEGs, right)  
1267 and genes shared by several groups (left), whereby the contributing groups are indicated as connected  
1268 dots (bottom). Horizontal bar plots visualize the size of DEGs per group.

1269 **(d)** Gene ontology enrichment analysis of upregulated DEGs obtained for each comparison G1-G5 vs G6.  
1270 Visualized are significant enrichments (adj. p-value  $< 0.05$ , q-value  $< 0.05$ ) for the union of top 10 terms per  
1271 comparison. Term ratio indicates the ratio of DEGs matching the term and the total gene number of that  
1272 term.

1273 **(e)** Box plots of normalized expression of selected DEGs, upregulated in at least one comparison.

1274 **(f)** Display of selected drug signatures from k-means cluster 13 from Fig. 5c showing high  $\Delta$ NES scores  
1275 throughout all patient groups compared to G6.

1276 **(g)** Visualization of recurring target genes in the G1 vs G6 comparison of cluster 13 signatures and their  
1277 frequency mapped onto the CoCena<sup>2</sup> network